US20060182802A1 - Rapidly disintegrable solid preparation - Google Patents

Rapidly disintegrable solid preparation Download PDF

Info

Publication number
US20060182802A1
US20060182802A1 US11/403,799 US40379999A US2006182802A1 US 20060182802 A1 US20060182802 A1 US 20060182802A1 US 40379999 A US40379999 A US 40379999A US 2006182802 A1 US2006182802 A1 US 2006182802A1
Authority
US
United States
Prior art keywords
weight
preparation
solid preparation
parts
exemplified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/403,799
Inventor
Toshihiro Shimizu
Masae Sugaya
Yoshinori Nakano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=16632688&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20060182802(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Priority to US11/403,799 priority Critical patent/US20060182802A1/en
Publication of US20060182802A1 publication Critical patent/US20060182802A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • A61K31/717Celluloses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50

Definitions

  • the present invention relates to a solid preparation having fast disintegrability in the oral cavity with the existence of saliva, in a little water, or in the stomach particularly a rapidly disintegrable solid preparation which is useful as an orally disintegrable solid preparation.
  • JP-A-9-48726 discloses an orally rapidly disintegrable preparation produced by wetting in a moldable way on humidifying. It comprises a drug and a material which can retain the shape after molding and drying. As such materials, a sugar, sugar alcohol and a water-soluble polymer material are exemplified.
  • JP-A-9-71523 discloses a tablet containing a drug, crystalline cellulose, a low-substituted hydroxypropylcellulose and a lubricant. It has fast disintegrability in the oral cavity.
  • EP-A 839526 discloses a solid pharmaceutical preparation containing a pharmacologically active ingredient, erythritol, crystalline cellulose and a disintegrator.
  • the present invention relates to:
  • a rapidly disintegrable solid preparation which comprises (i) a pharmacologically active ingredient, (ii) a sugar and (iii) a low-substituted hydroxypropylcellulose having 5% by weight or more to less than 7% by weight of hydroxypropoxyl group;
  • the pharmacologically active ingredients used in the present invention are in any condition such as solid, powdery, crystalline, oily and solution conditions.
  • pharmacologically active ingredients for example, one or more ingredient(s) selected from the group comprising nourishing and cordial agents, antipyretic-anodyne-anti-inflammatory drugs, psychotropics, antianxiety drugs, antidepressants, hypnotic-sedative drugs, spasmolytics, central nervous system drugs, brain metabolism ameliorating agents, brain circulation ameliorating agents, antiepileptics, sympathomimetics, gastrointestinal agents, antacids, antiulcer agents, antitussive-expetorants, antiemetics, respiratory accelerators, bronchodilators, antiallergic drugs, dental buccal drugs, antihistamines, cardiotonics, antiarrythmic drugs, diuretics, antihypertensive agents, vasoconstrictors, coronary vasodilators, peripheral vasodilators, antihypolipidemic agents,
  • vitamins such as vitamin A, vitamin D, vitamin E (such as d- ⁇ -tocopherol acetate and the like), vitamin B 1 (such as dibenzoylthiamine, fursultiamine hydrochloride and the like), vitamin B 2 (such as riboflavin butyrate and the like), vitamin B 6 (such as pyridoxine hydrochloride and the like), vitamin C (such as ascorbic acid, sodium L-ascorbate and the like) and vitamin B 12 (such as hydroxocobalamin acetate, cyanocobalamin and the like); minerals such as calcium, magnesium, iron and the like; proteins, amino acids, oligosaccharides, crude drugs and the like are exemplified.
  • vitamins such as vitamin A, vitamin D, vitamin E (such as d- ⁇ -tocopherol acetate and the like)
  • vitamin B 1 such as dibenzoylthiamine, fursultiamine hydrochloride and the like
  • vitamin B 2 such as riboflavin but
  • antipyretic-anodyne-antiinflammatory drugs for instance, aspirin, acetaminophen, ethenzamide, ibuprofen, diphenhydramine hydrochloride, dl-chlorpheniramine maleate, dihydrocodeine phosphate, noscapine, methylephedrine hydrochloride, phenylpropanolamine hydrochloride, caffeine, anhydrous caffein, serrapeptase, lysozyme chloride, tolfenamic acid, mefenamic acid, sodium diclofenac, flufenamic acid, salicylamide, aminopyrine, ketoprofen, indometacin, bucolome, pentazocine and the like are exemplified.
  • antipsychotics for instance, chlorpromazine, reserpine and the like are exemplified.
  • antianxiety drugs for instance, alprazolam, chlordiazepoxide, diazepam and the like are exemplified.
  • antidepressants for instance, imipramine, maprotiline hydrochloride, amphetamine and the like are exemplified.
  • estazolam for instance, estazolam, nitrazepam, diazepam, perlapine, sodium phenobarbital and the like are exemplified.
  • spasmolytics for instance, scopolamine hydrobromide, di-phenhydramine hydrochloride, papaverine hydrochloride and the like are exemplified.
  • central nervous system drugs for instance, citicoline and the like are exemplified.
  • brain metabolism ameliorating agents for instance, meclofenoxate hydrochloride and the like are exemplified.
  • antiepileptics for instance, phenytoin, carbamazepine and the like are exemplified.
  • isoproterenol hydrochloride As the sympathomimetics, for instance, isoproterenol hydrochloride and the like are exemplified.
  • stomachic-digestives such as diastase, saccharated pepsin, scopolia extract, cellulase AP3, lipase AP and cinnamon oil
  • agents for intestinal disorders such as berberine chloride, resistant lactic acid bacterium, Lactobacillus bifidus and the like are exemplified.
  • magnesium carbonate for instance, magnesium carbonate, sodium hydrogen-carbonate, magnesium aluminometasilicate, synthetic hydrotalcite, precipitated calcium carbonate, magnesium oxide and the like are exemplified.
  • antiulcer agents for instance, lansoprazole, omeprazole, rabeprazole, pantoprazole, famotidine, cimetidine, ranitidine hydrochloride and the like are exemplified.
  • antitussive-expetorants for instance, chloperastine hydrochloride, dextromethorphan hydrobromide, theophylline, potassium guaiacolsulfonate, guaiafenesin, codeine phosphate and the like are exemplified.
  • antiemetics for instance, difenidol hydrochloride, metoclopramide and the like are exemplified.
  • respiratory accelerators for instance, levallorphan tartrate and the like are exemplified.
  • bronchodilators for instance, theophylline, salbutanol sulfate and the like are exemplified.
  • antiallergic drugs for instance, amlexanox, seratrodast and the like are exemplified.
  • dental buccal drugs for instance, oxytetracycline, triamcinolone acetonide, chlorhexidine hydrochloride, lidocaine and the like are exemplified.
  • antihistamines for instance, diphenhydramine hydrochloride, promethazine, isothipendyl hydrochloride, dl-chlorpheniramine maleate and the like are exemplified.
  • cardiotonics for instance, caffeine, digoxin and the like are exemplified.
  • antiarrythmic drugs for instance, procainamide hydrochloride, propranolol hydrochloride, pindolol and the like are exemplified.
  • diuretics for instance, isosorbide, furosemide, thiazides such as HCTZ and the like are exemplified.
  • antihypertensive agents for instance, delapril hydrochloride, captopril, hexamethonium bromide, hydrazine hydrochloride, labetalol hydrochloride, manidipine hydrochloride, candesartan cilexetil, methyldopa, losartan, valsartan, eprosartan, irbesartan, tasosartan, telmisartan, and the like are exemplified.
  • vasoconstrictors for instance, phenylephrine hydrochloride and the like are exemplified.
  • coronary vasodilators for instance, carbocromen hydrochloride, molsidomine, verapamil hydrochloride and the like are exemplified.
  • peripheral vasodilators for instance, cinnarizine and the like are exemplified.
  • antihypolipidemic agents for instance, sodium cerivastatin , simvastatin, sodium pravastatin and the like are exemplified.
  • cholagogues for instance, dehydrocholic acid, trepibutone and the like are exemplified.
  • cephems such as cefalexin, cefaclor, amoxicillin, pivmecillinam hydrochloride, cefotiam hexetyl hydrochloride, cefadroxil, cefixime, cefditoren pivoxil, cefteram pivoxyl, cefpodoxime proxetil, cefotiam dihydrochloride, cefozopran hydrochloride, cefmenoxime hemihydrochloride, sodium cefsulodin; synthetic antibacterial agents such as ampicillin, ciclacillin, sodium sulbenicillin, nalidixic acid and enoxacin; monobactams such as sodium carumonam; penems; carbapenems and the like are exemplified.
  • chemotherapeutic drugs for instance, sulfamethizole, sulfamethizole hydrochloride, thiazosulfone and the like are exemplified.
  • antidiabetic agents for instance, tolbutamide, voglibose, pioglitazone hydrochloride, glibenclamide, troglitazone, rosiglitazone maleate, acarbose, miglitol, emigitate and the like are exemplified.
  • ipriflavone As the drugs for osteoporosis, for instance, ipriflavone and the like are exemplified.
  • skeletal muscle relaxants for instance, methocarbamol and the like are exemplified.
  • antivertigos for instance, meclizine hydrochloride, dimenhydrinate and the like are exemplified.
  • antirheumatism agents for instance, methotrexate, bucillamine, and the like are exemplified.
  • hormones for instance, sodium liothyronine, dexamethasone sodium phosphate, prednisolone, oxendolone, leuprorelin acetate and the like are exemplified.
  • alkaloid narcotics for instance, opium, morphine hydrochloride, ipecac, oxycodone hydrochloride, opium alkaloids hydrochlorides, cocaine hydrochloride and the like are exemplified.
  • sulfa drugs for instance, sulfamine, sulfisomidine, sulfamethizole and the like are exemplified.
  • blood coagulation inhibitors for instance, dicoumarol and the like are exemplified.
  • antitumor agents for instance, 5-fluorouracil, uracil, mitomycin and the like are exemplified.
  • nourishing and cordial agents antipyretic-anodyne-antiinflammatory drugs, hypnotic-sedative drugs, central nervous system drugs, gastrointestinal agents, antiulcer agents, antitussive-expetorants, antiallergic drugs, antiarrhythmic drugs, diuretics, antihypertensive agents, vasoconstrictors, coronary vasodilators, antihypolipidemic agents, antidiabetic agents, drugs for osteoporosis, skeletal muscle relaxants, antivertigos and the like are preferably used.
  • the pharmacologically active ingredients preferably used are antiulcer agents such as lansoprazole; antidiabetic agents such as voglibose and pioglitazone hydrochloride; and antihypertensive agents such as manidipine hydrochloride and candesartan cilexetil and the like are exemplified.
  • Two or more pharmacologically active ingredients can be optionally used in an admixture in a rapidly disintegrable solid preparation of this invention.
  • the pharmacologically active ingredient is optionally diluted by the diluents generally used in the fields of medical treatment and food. In addition, it is optionally treated for the purpose of masking the bitterness of the pharmacologically active ingredient.
  • the above pharmacologically active ingredient is used in an amount of, for example, 0.01 to 70 parts by weight, preferably 0.02 to 50 parts by weight, more preferably 0.05 to 30 parts by weight, per 100 parts by weight of the solid preparation.
  • sugars used in the present invention for example, sugar, starch sugar, lactose, honey and sugar alcohol are exemplified. Such sugars are optionally used in an admixture thereof with suitable ratio.
  • sugar for example, sucrose, coupling sugar, fructo-oligosaccharide, palatinose are exemplified.
  • starch sugar for example, glucose, maltose, powdered sugar, starch syrup, fructose and fruit sugar and the like are exemplified.
  • lactose for example, lactose, isomerized lactose (lactulose), reduced lactose (lactitol) and the like are exemplified.
  • honey various kinds of honey which are generally edible are exemplified.
  • sugar alcohol for example, sorbitol, mannitol, maltitol, reduced starch saccharide, xylitol, reduced paratinose, erythritol, and the like are exemplified.
  • erythritol is optionally one used which is produced by fermentation using glucose as a starting material with yeast in general and has at most 50 mesh of the particle size.
  • Such erythritol is commercially available [for example, from Nikken Chemicals Co., Ltd. (Japan)].
  • the above sugars are preferably water-soluble sugars.
  • the water-soluble sugars mean any water-soluble sugars which need at most 30 ml of water when 1 g of sugar is added into water and then dissolved within 30 minutes at 20° C. by strongly shaking every 5 minutes for 30 seconds.
  • the sugar is preferably the sugar alcohol, more preferably mannitol or erythritol.
  • the sugar is used in an amount of 5 to 97 parts by weight, preferably 10 to 90 parts by weight, per 100 parts by weight of the solid preparation in case of the solid preparation not comprising fine granules.
  • the sugar is used in an amount of 5 to 97 parts by weight, preferably 10 to 90 parts by weight, per 100 parts by weight of the rest of the solid preparation other than the fine granules in case of the solid preparation comprising fine granules.
  • mannitol or erythritol is usually used in an amount of 5 to 90 weight %, preferably 10 to 80 weight %, more preferably 20 to 80 weight %, especially preferably 50 to 80 weight % relative to the whole solid preparation in case of the solid preparation not comprising fine granules.
  • mannitol or erythritol is usually used in an amount of 5 to 90 weight %, preferably 10 to 80 weight %, more preferably 20 to 80 weight %, especially preferably 50 to 80 weight % relative to the rest of the solid preparation other than the fine granules in case of the solid preparation comprising fine granules.
  • the “low-substituted hydroxypropylcellulose having 5% by weight or more to less than 7% by weight of hydroxypropoxyl group (hereinafter, optionally referred to L-HPC)” used in the present invention can be produced in accordance with well-known methods, for example, methods described in JP-B-57-53100 or its analogous methods thereof.
  • alkaline cellulose containing free alkaline and propylene oxide are reacted to obtain the crude low-substituted hydroxypropylcellulose containing free alkaline.
  • raw material pulp such as wood pulp and cotton leader is immersed in 10 to 50% concentration of aqueous solution of sodium hydroxide, and pressed to obtain the alkaline cellulose of which NaOH/cellulose ratio is 0.1 to 1.2 (ratio by weight).
  • the crude low-substituted hydroxypropylcellulose containing free alkaline is obtained by reacting the resulting alkaline cellulose and propylene oxide with stirring at 20 to 90° C. for 2 to 8 hours.
  • Propylene oxide is used in an amount so that the content of hydroxypropoxyl group in the desired low-substituted hydroxypropylcellulose can be 5% or more by weight to less than 7% by weight.
  • the crude low-substituted hydroxypropylcellulose containing free alkaline is dispersed in water or hot water containing 5 to 80% of acid which is need to neutralize the all amount of alkaline, and a part of the crude low-substituted hydroxypropylcellulose containing free alkaline is dissolved therein. Further, acid is added to neutralize the remained alkaline.
  • the particle diameter of L-HPC used in the present invention is, for example, 5 to 60 ⁇ m as average particle diameter. Preferably, it is 10 to 40 ⁇ m as average particle diameter.
  • L-HPC having relatively large particle diameter for example, L-HPC having 26 to 40 ⁇ m of average particle diameter
  • a pharmaceutical preparation being superior in disintegrability can be produced.
  • L-HPC having relatively small particle diameter for example, L-HPC having 10 to 25 ⁇ m of average particle diameter
  • the particle diameter of L-HPC can be suitably selected according to the character of the desired pharmaceutical preparation.
  • the L-HPC in the present invention is used in an amount of 3 to 50 parts by weight, preferably 5 to 40 parts by weight, per 100 parts by weight of the solid preparation in case of the solid preparation not comprising fine granules.
  • the L-HPC in the present invention is used in an amount of 3 to 50 parts by weight, preferably 5 to 40 parts by weight, per 100 parts by weight of the rest of the solid preparation other than the fine granules in case of the solid preparation comprising fine granules.
  • the dosage form of the rapidly disintegrable solid preparation of the present invention for example, tablet, granule, fine granule and the like, preferably tablet is exemplified.
  • rapidly disintegrable tablets such as an orally disintegrable tablet and a tablet disintegrable in water, the orally disintegrable tablet is preferable.
  • the rapidly disintegrable solid preparation of the present invention may further contain a variety of additives which are commonly used in the manufacture of preparations in general dosage forms.
  • Amount of such additives to be used is one commonly used in the manufacture of preparations in general dosage forms.
  • additives for example, binders, acids, foaming agents, artificial sweeteners, flavorants, lubricants, colorants, stabilizers, excipients, disintegrators and the like are exemplified.
  • binders for example, hydroxypropylcellulose, hydroxypropylmethylcellulose, crystalline cellulose, pregelatinized starch, polyvinylpyrrolidone, gum arabic powder, gelatin, pullulan and the like are exemplified. These two or more binders can be used in an admixture in a given ratio.
  • the use of crystalline cellulose as the binder provides the solid preparation which exhibits more excellent strength of the preparation while retaining excellent fast disintegrability in the oral cavity.
  • crystalline cellulose microcrystalline cellulose is also included.
  • the “crystalline cellulose” includes a refined one having partially ⁇ -cellulose depolymerization.
  • crystalline cellulose for example, CEOLUS KG 801, Avicel PH 101, Avicel PH 102, Avicel PH 301, Avicel PH 302, Avicel RC-A591 NF (crystalline cellulose•carmellose sodium), Avicel RC-591 (crystalline cellulose•carmellose sodium) and the like are concretely exemplified.
  • CEOLUS KG 801 referred to as highly moldable crystalline cellulose is preferably used.
  • Such crystalline celluloses are optionally used in an admixture thereof with suitable ratio.
  • Such crystalline celluloses can be commercially available (manufactured by Asahi Chemical Industry Co., Ltd. (Japan)).
  • the crystalline cellulose is used in an amount of, for example, 1 to 50 parts by weight, preferably 2 to 40 parts by weight, more preferably 2 to 20 parts by weight, per 100 parts by weight of the solid preparation in case of the solid preparation not comprising fine granules.
  • the crystalline cellulose is used in an amount of, for example, 1 to 50 parts by weight, preferably 2 to 40 parts by weight, more preferably 2 to 20 parts by weight, per 100 parts by weight of the solid preparation apart from fine granules in case of the solid preparation comprising fine granules.
  • acids for example, citric acid, tartaric acid, malic acid and the like are exemplified.
  • foaming agents for example, sodium bicarbonate and the like are exemplified.
  • artificial sweeteners for example, saccharin sodium, dipotassium glycyrrhizinate, aspartame, stevia, thaumatin and the like are exemplified.
  • flavorants for example, lemon, lemon lime, orange, mentol, strawberry and the like are exemplified.
  • lubricants for example, magnesium stearate, sucrose fatty acid ester, polyethylene glycol, talc, stearic acid and the like are exemplified.
  • Use of polyethylene glycol as the lubricant provides the stable solid preparation of which the decomposition over time of the pharmacologically active ingredient is controlled. At that time, polyethylene glycol is used in an amount of, for example, 0.01 to 10 parts by weight, preferably 0.1 to 5 parts by weight, per 100 parts by weight of the solid preparation in case of the solid preparation not comprising fine granules.
  • polyethylene glycol is used in an amount of, for example, 0.01 to 10 parts by weight, preferably 0.1 to 5 parts by weight, per 100 parts by weight of the solid preparation apart from fine granules in case of the solid preparation comprising fine granules.
  • colorants for example, various food colorants such as Food Yellow No. 5, Food Red No. 2, Food Blue No. 2 and the like; food lakes, red iron oxide and the like are exemplified.
  • a basic substance in the case of the basic pharmacologically active ingredient and an acidic substance in the case of the acidic pharmacologically active ingredient are exemplified.
  • excipients for example, lactose, sucrose, D-mannitol, starch, corn starch, crystalline cellulose, light silicic anhydride, titanium oxide and the like are exemplified.
  • disintegrators for example, disintegrators called super disintegrators such as crospovidone [manufactured by ISP Inc. (U.S.A.), BASF (Germany)], croscarmellose sodium [FMC-Asahi Chemical Industry Co., Ltd. (Japan)], carmellose calcium [Gotoku Chemical (Yakuhin), (Japan)]; hydroxypropylcellulose; low-substituted hydroxypropylcellulose; carboxymethylstarch sodium [Matsutani Chemical Co., Ltd. (Japan)]; corn starch and the like are exemplified.
  • crospovidone is preferably used.
  • Such two or more disintegrators are optionally used in an admixture thereof with suitable ratio.
  • any cross-linked homopolymer such as 1-ethenyl-2-pyrrolidinone homopolymer may be used, and usually crospovidone having a molecular weight of at least 1,000,000 is used.
  • crospovidone which is commercially available, for example, Cross-linked povidone, Kollidone CL [manufactured by BASF (Germany)], Polyplasdone XL, Polyplasdone XL-10, INF-10 [manufactured by ISP Inc., (U.S.A.)], polyvinylpolypyrrolidone, PVPP, 1-vinyl-2-pyrrolidinone homopolymer and the like are concretely exemplified.
  • Two or more of these disintegrants can be as a mixture in a given ratio.
  • crospovidone solely or (ii) crospovidone and another disintegrant(s) is preferably used.
  • Such disintegrator is used in an amount of, for example, 0.1 to 20 parts by weight, preferably 1 to 10 parts by weight, more preferably 3 to 7 parts by weight, per 100 parts by weight of the solid preparation in case of the solid preparation not comprising fine granules.
  • such disintegrator is used in an amount of, for example, 0.1 to 20 parts by weight, preferably 1 to 10 parts by weight, more preferably 3 to 7 parts by weight, per 100 parts by weight of the rest of the solid preparation other than the fine granules in case of the solid preparation comprising fine granules.
  • a basic inorganic salt is preferably incorporated to stabilize the pharmacologically active ingredient in the solid preparation.
  • the “basic inorganic salt” includes, for example, a basic inorganic salt of sodium, potassium, magnesium and/or calcium, preferably a basic inorganic salt of magnesium and/or calcium. Among others, preferred is a basic inorganic salt of magnesium.
  • the basic inorganic salt of sodium includes, for example, sodium carbonate, sodium hydrogencarbonate, sodium phosphate, sodium hydrogenphosphate and the like.
  • the basic inorganic salt of potassium includes, for example, potassium carbonate, potassium hydrogencarbonate, potassium phosphate, potassium hydrogenphosphate, potassium sodium carbonate and the like.
  • the basic inorganic salt of magnesium includes, for example, heavy magnesium carbonate, magnesium carbonate, magnesium oxide, magnesium hydroxide, magnesium metasilicate aluminate, magnesium silicate aluminate, magnesium silicate, magnesium aluminate, synthetic hydrotalcite [Mg 6 Al 2 (OH) 16 .CO 3 .4H 2 O], aluminum magnesium hydroxide [2.5MgO.Al 2 O 3 .xH 2 O] and the like.
  • the basic inorganic salt of calcium includes, for example, precipitated calcium carbonate, calcium hydroxide, and the like.
  • the preferable examples of the “basic inorganic salt” are magnesium basic inorganic salt, and more preferable examples include heavy magnesium carbonate, magnesium carbonate, magnesium oxide, magnesium hydroxide, and the like.
  • Such basic inorganic salt of magnesium or calcium, and the like has a basic pH (not less than 7) when it is in the form of a 1% aqueous solution or suspension.
  • Two or more of these basic inorganic salts can be used as a mixture in a given ratio.
  • the amount of the basic inorganic salt to be used is appropriately selected depending on the kind of the basic inorganic salt and is, for instance, 0.3 to 200 parts by weight, preferably 1 to 100 parts by weight, more preferably 10 to 50 parts by weight, especially preferably 20 to 40 parts by weight relative to the pharmacologically active ingredient.
  • the rapidly disintegrable preparation of the present invention can be used in any solid dosage form such as tablet, granule, fine granule and the like.
  • the tablet can contain fine granules.
  • the fine granules may contain the pharmacologically active ingredient.
  • the fine granule can contain a core together with or separately from the pharmacologically active ingredient.
  • a core for example, (1) a spherical granulated product comprising crystalline cellulose and lactose [e.g., a spherical granulated product being 100 to 200 ⁇ m and comprising crystalline cellulose (3 parts) and lactose (7 parts) (Nonpareil 105 (trade name), manufactured by Freund Industrial Co., Ltd. (Japan)), a spherical granulated product being 150 to 250 ⁇ m and comprising crystalline cellulose (3 parts) and lactose (7 parts) (Nonpareil NP-7:3 (trade name), manufactured by Freund Industrial Co., Ltd.
  • the core is optionally coated with the pharmacologically active ingredient and the like, and further coated for masking taste or smell and/or for imparting enteric dissolubility or sustained-release property by well known methods.
  • a core forms a fine granule comprising the pharmacologically active ingredient.
  • enteric-coated polymers e.g., cellulose acetate phthalate (CAP), methacrylate copolymer L, methacrylate copolymer LD (Eudragit L30D-55 (trade name; manufactured by Rohm GmbH (Germany))
  • methacrylate copolymer S hydroxypropylmethylcellulose phthalate, hydroxymethylcellulose acetate succinate, hydroxypropylmethylcellulose acetate succinate, KolllCoat MAE30DP (trade name; manufactured by BASF (Germany)), Polyquid PA-30 (trade name; manufactured by SanyoKasei (Japan)), carboxymethylethylcellulose, shellac, methacrylate copolymer [e.g., Eudragit NE30D (trade name), Eudragit RL30D (trade name), Eudragit RS30D (trade name) and the like] triethyl citrate, polyethylene glycol, acetylated mono
  • the “fine granules” in the present invention can be produced by a known granulation method.
  • the “granulation method” includes, for example, rolling granulation method (e.g., centrifugal rolling granulation, etc.), fluidized-bed granulation (e.g., rolling fluidized-bed granulation, fluidized granulation, etc.), stirring granulation and the like.
  • rolling granulation method e.g., centrifugal rolling granulation, etc.
  • fluidized-bed granulation e.g., rolling fluidized-bed granulation, fluidized granulation, etc.
  • stirring granulation e.g., stirring granulation and the like.
  • preferred is fluidized-bed granulation method, more preferred is rolling fluidized-bed granulation method.
  • rollering granulation method includes a method using “CF apparatus” manufactured by Freund Industrial Co., Ltd. (Japan) and the like.
  • Rolling fluidized-bed granulation method include methods using “SPIR-A-FLOW”, “multi plex” manufactured by Powrex Corp. (Japan), “New-Marumerizer” manufactured by Fuji Paudal Co., Ltd. (Japan), and the like.
  • the method for spraying the mixture can be suitably selected in accordance with the kind of granulator, and may be, for example, any one of a top spray method, a bottom spray method, a tangential spray method, and the like. Among others, a tangential spray method is preferred.
  • the “fine granules” in the present invention can be coated with any other ingredient including the active ingredient and the others, by a conventional coating method or its analogous method.
  • a method which comprises coating a core comprising crystalline cellulose and lactose with an acid-labile physiologically active substance is employed in case that pharmacologically active ingredient is an acid-labile physiologically active substance.
  • coating method which comprises coating a core comprising crystalline cellulose and lactose with an acid-labile physiologically active substance, if necessary together with a basic inorganic salt, binders, lubricants, excipients, a water-soluble polymer, etc.
  • coating layer a basic inorganic salt, binders, lubricants, excipients, a water-soluble polymer, etc.
  • coating layer a method which comprises coating a core with an acid-labile physiologically active substance and a basic inorganic salt, and then further with binders, lubricants, excipients, a water-soluble polymer, etc.
  • the average particle diameter of the “cores” is 250 ⁇ m or less, preferably 50 to 250 ⁇ m, more preferably 100 to 250 ⁇ m, especially preferably 100 to 200 ⁇ m.
  • the “cores” having the above average particle diameter include particles which all pass through a #50 sieve (300 ⁇ m), particles where 5 w/w % or less of the total remain on a #60 sieve (250 ⁇ m), and particles where 10 w/w % or less of the total pass through a #282 sieve (53 ⁇ m).
  • the specific volume of the “core” is 5 ml/g or less, preferably 3 ml/g or less.
  • Examples of the “core” include:
  • spherical granulated product comprising crystalline cellulose and lactose includes, for example (i) a spherical granulated product being 100 to 200 ⁇ m and comprising crystalline cellulose (3 parts) and lactose (7 parts) [e.g., Nonpareil 105 (70-140) (particle diameter of 100 to 200 ⁇ m), manufactured by Freund Industrial Co., Ltd. (Japan)], (ii) a spherical granulated product being 150 to 250 ⁇ m and comprising crystalline cellulose (3 parts) and lactose (7 parts) [e.g., Nonpareil NP-7:3, manufactured by Freund Industrial Co., Ltd.
  • a spherical granulated product being 100 to 200 ⁇ m and comprising crystalline cellulose (3 parts) and lactose (7 parts) [e.g., Nonpareil NP-7:3, manufactured by Freund Industrial Co., Ltd.
  • a spherical granulated product being 100 to 200 ⁇ m and comprising crystalline cellulose (4.5 parts) and lactose (5.5 parts) [e.g., Nonpareil 105T (70-140) (particle diameter of 100 to 200 ⁇ m), manufactured by Freund Industrial Co., Ltd. (Japan)], (iv) a spherical granulated product being 150 to 250 ⁇ m and comprising crystalline cellulose (5 parts) and lactose (5 parts) [e.g., Nonpareil NP-5:5, manufactured by Freund Industrial Co., Ltd. (Japan)], and the like.
  • the “core” includes, for example, preferably the spherical granulated product comprising crystalline cellulose and lactose, more preferably the spherical granulated material comprising crystalline cellulose and lactose and containing 50 weight % or more of lactose relative to the whole solid preparation.
  • a core comprising 40 to 50 weight % of crystalline cellulose and 50 to 60 weight % of lactose.
  • the spherical granulated product comprising crystalline cellulose and lactose, more preferably the spherical granulated product with a diameter of 100 to 200 ⁇ m and comprising crystalline cellulose (4.5 parts) and lactose (5.5 parts).
  • the “core” may contain the physiologically active substance such as the above described pharmacologically active ingredient. Also, the “core” may not contain the physiologically active substance because the release of the physiologically active substance can be controlled by a coating layer containing the physiologically active substance.
  • the “core” is preferably as uniform a sphere as possible, for reducing the irregularity of the coating, in addition to being a powdery core.
  • the ratio of the “coating layer” to the “core” can be selected within the range in which it is possible to control dissolution of the physiologically active substance and particle size of the composition, for example, usually 50 to 400 parts by weight relative to 100 parts by weight of the core.
  • the coating layer may be constructed by plural layers. At least one layer of the plural layers must contain the physiologically active substance.
  • the combination of various layers such as a coating layer not containing the active ingredient, a base coating layer, and an enteric coating layer which constitute the coating layer can be suitably selected.
  • the above physiologically active substance and the water-soluble polymer can be employed in an admixture thereof.
  • the admixture may be a solution or a dispersion, and can be prepared by using an organic solvent such as water or ethanol or an admixture thereof.
  • the concentration of the water-soluble polymer in the admixture varies according to the ratio of the physiologically active substance and the additives, and is usually 0.1 to 50 weight %, preferably 0.5 to 10 weight % relative to the whole solid preparation, in order to retain the binding strength of the physiologically active substance to the core and maintain the viscosity of the mixture so as not to reduce the workability.
  • the concentration of the physiologically active substance in each layer may be changed successively or gradually by selecting for the content ratio or viscosity of the water-soluble polymer or by successive coating with mixtures varying in the ratio of the physiologically active substance and the other additives.
  • it may be coated with a mixture in which the content ratio of the water-soluble polymer is out of the range of 0.1 to 50 weight %, as long as the coating layer as a whole contains 0.1 to 50 weight % of the water-soluble polymer.
  • the coating layer optionally comprises some layers such that the inactive layer may block each layer containing the physiologically active substance.
  • the core may be coated by employing each mixture together or separately.
  • the above coated material is dried, and passed through sieves to obtain a “composition” having uniform size. Because the form of the composition is usually according to the core, a fine granule being in the form of a rough sphere can be obtained.
  • the sieve may be employed, for example a #50 circular sieve (300 ⁇ m). The composition is obtained by selecting those which pass through the #50 circular sieve.
  • the “fine granule” in the present invention can be produced in accordance with in the same manner as above granulation method, for example, a method which comprises coating the composition with an enteric coating layer, in order to protect the physiologically active substance or to impart enteric dissolution.
  • the composition coated with an enteric coating layer may be further coated by a water-soluble sugar alcohol, preferably mannitol. In such case, the strength of the orally disintegrable tablet comprising fine granules is improved.
  • the “enteric coating layer” is preferably a layer having 20 to 70 ⁇ m, preferably 30 to 50 ⁇ m of thickness and coating the whole surface of the composition containing the physiologically active substance. Accordingly, the smaller particle diameter of the composition, the higher the weight % of the enteric coating layer in the whole fine granule. In the fine granule of the present invention, the “enteric coating layer” is 30 to 70 weight %, preferably 50 to 70 weight %, of the fine granule as a whole.
  • the “enteric coating layer” are optionally constructed by plural (e.g., 2 or 3) layers.
  • the used is a method which comprises coating a composition with an enteric coating layer having polyethyleneglycol, and then with an enteric coating layer having triethyl citrate, followed by being coated with an enteric coating layer having polyethyleneglycol.
  • the rapidly disintegrable solid preparation of the present invention can be produced in accordance with a conventional method or its analogous method in the field of pharmaceutical preparation.
  • a method comprising blending the pharmacologically active ingredient, the sugar and the low-substituted hydroxypropylcellulose having 5% by weight or more to less than 7% by weight of hydroxypropoxyl group after adding water if needed, molding, and then drying if needed is exemplified.
  • the rapidly disintegrable solid preparation of the present invention can be produced also without water.
  • a conventional molding method or its analogous method can be applied by using appropriate ingredients selected from the above-mentioned ones including the fine granules.
  • Preferred example of the method for the orally disintegrable tablet having the fine granules of the coated cores comprises:
  • the molding procedure can be carried out, for instance, by tabletting with a pressure of 0.5 to 3 ton/cm 2 , preferably 1 to 2 ton/cm 2 by using a single-punch tabletting machine [Kikusui Seisakusho (Japan)] or a rotary type tabletting machine [Kikusui Seisakusho (Japan)] when a solid preparation is a tablet, especially an orally disintegrable tablet.
  • the drying procedure can be carried out by any techniques such as vacuum drying, fluidized-bed drying and the like used to dry the general pharmaceutical preparation.
  • the blending procedure can be carried out by any conventional blending techniques such as admixing, kneading, granulating and the like.
  • the blending procedure is carried out by using an apparatus such as Vertical Granulator VG10 [manufactured by Powrex Corp. (Japan)], Universal Kneader [manufactured by Hata Iron Works Co., Ltd. (Japan)], fluidized bed granulator LAB-1 and FD-3S [manufactured by Powrex Corp. (Japan)], centrifugal fluidized coating granulator MP-10, MP-400 [manufactured by Powrex Corp. (Japan)] and the like.
  • Vertical Granulator VG10 manufactured by Powrex Corp. (Japan)]
  • Universal Kneader manufactured by Hata Iron Works Co., Ltd. (Japan)
  • fluidized bed granulator LAB-1 and FD-3S fluidized bed granulator LAB-1 and FD-3
  • coating means also partial coating and adhesion or adsorption in addition to coating the whole surface of an object (e.g., core) which is to be coated.
  • Spherical means also forms having a curved surface such as forms having elliptic cross sections, and forms in the shapes of eggplants and drops in addition to spheres.
  • Average particle diameter means volume based distribution median diameter (median diameter: 50% particle diameter from cumulative distribution), unless otherwise specified. It can be measured by, for example, a laser diffraction particle distribution measurement method. Concretely exemplified is a method using Raiser Diffraction Analyzer, type: HEROS RODOS [trade name; manufactured by Sympatec (Germany)].
  • fine granules have an average particle diameter of about 400 ⁇ m or less, in order that roughness is not felt in the mouth.
  • the average particle diameter of the fine granules is 300 to 400 mm.
  • the particle diameter is substantially 425 ⁇ m or less, and preferably substantially 400 ⁇ m or less.
  • the particle diameter is substantially 300 to 425 ⁇ m, more preferably 300 to 400 ⁇ m.
  • the particle diameter is substantially 425 ⁇ m or less
  • composition may contain water-soluble polymers, the above binders, lubricants, excipients and the like in common use as pharmaceutical materials.
  • the amount of such water-soluble polymers, binders, lubricants, and excipients is selected from amounts commonly employed in the manufacture of preparations in general dosage forms.
  • the “water-soluble polymer” includes, for example, a water-soluble polymer which is soluble in ethanol (i.e., an ethanol-soluble water-soluble polymer) such as a cellulose derivative (e.g., hydroxypropyl cellulose, which may be referred to as “HPC” hereinafter), polyvinylpyrrolidone, etc.; a water-soluble polymer which is insoluble in ethanol (i.e., an ethanol-insoluble water-soluble polymer) such as a cellulose derivative (e.g., hydroxypropylmethyl cellulose, which may be referred to as “HPMC” hereinafter, methyl cellulose, carboxymethyl cellulose sodium, etc.), sodium polyacrylate, polyvinyl alcohol, sodium alginate, and guar gum, etc.
  • a water-soluble polymer which is soluble in ethanol i.e., an ethanol-soluble water-soluble polymer
  • a cellulose derivative e.g., hydroxypropylmethyl cellulose
  • the dissolution of drugs can be controlled by employing them in combination with the ethanol-soluble water-soluble polymer and ethanol-insoluble water-soluble polymer or by employing them in combination with some water-soluble polymers having different viscosity.
  • the “water-soluble polymer” is preferably, a cellulose derivative such as HPC, HPMC, and methyl cellulose, and polyvinyl alcohol. More preferred is a cellulose derivative such as HPC, HPMC.
  • the “HPC” contains, for example, about 53.4 to 77.5 weight %, more preferably about 60 to 70 weight %, of hydroxypropoxyl group.
  • the viscosity of 2 weight % aqueous solution of HPC at 20° C. is usually about 1 to 150,000 cps (centipoise).
  • HPC hydroxypropyl cellulose defined in Japanese Pharmacopoeia may be employed.
  • all viscosity of HPC is a value of 2 weight % aqueous solution at 20° C.
  • HPMC is a mixed ether which is connected by a methoxy group and a hydroxypropoxy group.
  • the content of the methoxy group of HPMC is, for example, about 19 to 30 weight %.
  • the content of the hydroxypropoxy group is, for example, about 4 to 12 weight %.
  • the viscosity of 2 weight % aqueous solution of HPMC at 20° C. is usually about 1 to 40,000 centistokes.
  • HPMC may be employed hydroxypropylmethyl cellulose 2208 defined by Japanese Pharmacopoeia, hydroxypropylmethyl cellulose 2906 defined by Japanese Pharmacopoeia, hydroxypropylmethyl cellulose 2910 defined by Japanese Pharmacopoeia, and so forth. Hydroxypropyl cellulose(s) may be employed alone or in an admixture of two or more thereof.
  • the content of the water-soluble polymer such as HPC and/or HPMC is usually about 0.1 to 50 weight %, preferably about 1 to 30 weight %, as against the whole “composition” containing the physiologically active substance, in order to control the dissolution of the physiologically active substance in the composition containing the physiologically active substance and retain a high content of the physiologically active substance.
  • the “fine granules” may contain, for example, titanium oxide as a masking agent.
  • the diameter of the “orally disintegrable tablet” of the present invention is about 5 to 20 mm, preferably about 7 to 15 mm, more preferably about 8 to 13 mm.
  • the “orally disintegrable tablet” optionally may not comprise lubricant inside the tablet.
  • the diameter of the tablet is about 5 to 10 mm, preferably about 5 to 8 mm.
  • the size of the capsule is preferably a #2 capsule or less.
  • the rapidly disintegrable solid preparation of the present invention thus obtained exhibits fast disintegrability or dissolubility in the oral cavity, water or stomach, and suitable strength of the preparation. Further the rapidly disintegrable solid preparation of the present invention is improved in chalky taste and has no roughness.
  • the orally disintegration time of the rapidly disintegrable solid preparation of the present invention (the time for healthy male or female adults to complete disintegration by buccal saliva) is usually 5 to 50 seconds, preferably 5 to 40 seconds, more preferably 5 to 35 seconds.
  • the disintegration time in the stomach of the rapidly disintegrable solid preparation of the present invention (the time for healthy male or female adults to complete disintegration) is shorter than that of the normal preparation such as a normal tablet.
  • the disintegration time of the rapidly disintegrable solid preparation of the present invention in water is usually 5 to 40 seconds, preferably 5 to 30 seconds, more preferably 5 to 25 seconds.
  • the strength of the rapidly disintegrable solid preparation of the present invention is usually 2 to 20 kg, preferably 4 to 15 kg.
  • the rapidly disintegrable solid preparation of the invention is especially used for an orally disintegrable tablet and can be administered without water or together with water.
  • administration methods there are listed (1) a method of administration by dissolution or disintegration together with a little water, or without water and with saliva in the oral cavity, not to be swallowed as it is, or (2) a method of administration with water, where it is swallowed as it is. Also, the tablet may be administered dissolved or disintegrated with water.
  • the “orally disintegrable tablet” of the present invention is advantageously used in (a) cases where administration without water is necessary, (b) cases of administration to a patients who have difficulty in swallowing tablets, or (c) cases of administration to the aged or to children where there is a fear of blocking the throat if it is in usual tablet form.
  • the rapidly disintegrable solid preparation of the present invention can be safely administered orally to mammals such as mouse, rat, rabbit, cat, dog, bovine, horse, monkey, human and the like.
  • the dosage amount of the rapidly disintegrable solid preparation varies depending on a pharmacologically active ingredient, a subject, a kind of disease and the like, the dosage amount is selected so that the dosage amount of the pharmacologically active ingredient can be an effective amount.
  • the orally disintegrable tablet is preferably used for antipyretic agents, analgesic agents, anti-inflammatory agents, antianxiety drugs, antitussive-expectorants, anti motion sickness agents, drugs for prevention and treatment for car-sickness, and the like.
  • the orally disintegrable tablet is preferably used for preventing and/or treating hypertension, hyperlipemia, diabetes, bronchial asthma, cerebrovascular diseases, and the like.
  • the rapidly disintegrable solid preparation of the present invention is useful for treatment and prevention of digestive ulcer (such as gastric ulcer, duodenal ulcer, anastomic ulcer, Zollinger-Ellison syndrome), gastritis, reflex esophagitis and the like; eradication of H.
  • digestive ulcer such as gastric ulcer, duodenal ulcer, anastomic ulcer, Zollinger-Ellison syndrome
  • gastritis such as gastric ulcer, duodenal ulcer, anastomic ulcer, Zollinger-Ellison syndrome
  • gastritis such as gastric ulcer, duodenal ulcer, anastomic ulcer, Zollinger-Ellison syndrome
  • reflex esophagitis and the like
  • eradication of H such as gastric ulcer, duodenal ulcer, anastomic ulcer, Zollinger-Ellison syndrome
  • the dosage amount of the preparation per an adult is 0.5 to 1500 mg/day, preferably 5 to 150 mg/day, as lansoprazole.
  • the rapidly disintegrable solid preparation of the present invention is useful for treatment and prevention of obesity, adiposis, lipemia, diabetes mellitus and the like.
  • the dosage amount of the preparation per an adult is 0.01 to 30 mg/day, preferably 0.1 to 3 mg/day, as voglibose.
  • the rapidly disintegrable solid preparation can be administered once a day, or 2 to 3 times separately a day.
  • the rapidly disintegrable solid preparation of the present invention is useful for treatment and prevention of circulatory system diseases such as hypertension, ischemic heart disease (e.g., angina pectori, myocardial infarction and the like), cerebral and peripheral circulatory disorders (e.g., cerebral infarction, transient ischemic attack, constriction of renal artery and the like) and the like.
  • the dosage amount of the preparation per an adult (body weight: 60 kg) is 1 to 200 mg/day, preferably 10 to 20 mg/day, as manidipine hydrochloride.
  • the rapidly disintegrable solid preparation is usually administered once a day after breakrapidly.
  • the rapidly disintegrable solid preparation of the present invention is useful as the insulin resistance improving agent and the like, and for treatment and prevention of diabetes mellitus.
  • the dosage amount of the preparation per an adult is 7.5 to 60 mg/day, preferably 15 to 45 mg/day, as pioglitazone hydrochloride.
  • the rapidly disintegrable solid preparation can be administered once a day, or 2 to 3 times separately a day.
  • the rapidly disintegrable solid preparation of the present invention is useful for treatment and prevention of hypertension, heart diseases, cerebral apoplexy, renal diseases and the like.
  • the dosage amount of the preparation per an adult is 1 to 50 mg/day, preferably 2 to 30 mg/day, as candesartan cilexetil.
  • % means % by weight.
  • the content of hydroxypropoxyl group is measured in accordance with the methods described in Japanese Pharmacopoeia (e.g., 13th edition).
  • the physical properties (hardness and disintegration time) of the tablets were determined by the following test methods.
  • Determination was carried out with a tablet hardness tester [manufactured by Toyama Sangyo Co. Ltd. (Japan)]. The test was performed in 10 runs and mean values were shown.
  • An alkaline cellulose comprising 24.1% of NaOH, 1.7% of Na 2 CO 3 , 42.9% of cellulose, 31.8% of H 2 O was obtained by immersing wood pulp in 49% aqueous solution of sodium hydroxide and then by pressing it.
  • a reactor was charged with 100 parts by weight of the alkaline cellulose. Then, nitrogen gas replacement was carried out. After the replacement, 5 parts by weight of propylene oxide was charged in the reactor and reacted with stirring at 40° C. for 1 hour, at 50° C. for 1 hour and at 70° C. for 1 hour to provide 103 parts by weight of a reactant.
  • a kneader was charged with 2.5 parts by weight of hot water at 65° C. and 0.13 parts by weight of glacial acetic acid (40% by weight against equivalent for neutralization, initial neutralized acid) and therein, 1 part by weight of the above resulting alkaline cellulose was dispersed. Then, the temperature was adjusted at 30° C. to dissolve a part of the reactant, and 0.20 part by weight of glacial acetic acid (remain of equivalent for neutralization, complete neutralized acid) to provide a processed fiber product containing a part of dissolution and a part of deposit.
  • the resulting product was washed with hot water at 80° C., drained, dried, ground by means of high rolling impact grinder, and sifted by means of a 100 mesh sieve to provide the powder of low-substituted hydroxypropylcellulose LH-33 (content of hydroxypropoxyl group: 5.8% by weight, average particle diameter: 17.8 ⁇ m).
  • Powders of low-substituted hydroxypropylcellulose LH-23, which have a little bigger average particle diameter (content of hydroxypropyl group: 5.7% by weight, average particle diameter: 30.8 ⁇ m) were obtained in the same manner as in Reference Example 1.
  • a centrifugal fluidized coating granulator [manufactured by Powrex Corp. (Japan), MP-10] was charged with 900 g of Nonpareil 105 (trade name) (particle diameter: 100 to 200 ⁇ m). While the inlet air temperature and the outlet air temperature were controlled at 70° C. and 30° C. respectively, the Nonpareil was coated by spraying a spray liquid of the following composition prepared in advance in accordance with the tangential spray method at the spray rate of 22 g/min. Then, drying was carried out for 10 minutes. The resulting granules were sieved through a #60 circular sieve (250 ⁇ m) and a #100 circular sieve (150 ⁇ m) to provide 2186 g of powders (150 to 250 ⁇ m) having a core.
  • a centrifugal fluidized coating granulator [manufactured by Powrex Corp. (Japan), MP-10] was charged with 2040 g of the above powders having a core. While the inlet air temperature and the outlet air temperature were controlled at 75° C. and 40° C. respectively, an undercoating liquid of the following composition prepared in advance was sprayed in accordance with the tangential spray method at the spray rate of 13 g/min. 2145 g of film-undercoated powders having a core was obtained.
  • a centrifugal fluidized coating granulator [manufactured by Powrex Corp. (Japan), MP-10] was charged with 1710 g of the above film-undercoated powders having a core. While the inlet air temperature and the outlet air temperature were controlled at 70° C. and 40° C. respectively, an enteric film coating liquid of the following composition prepared in advance was sprayed in accordance with the tangential spray method at the spray rate of 19 g/min. Then, drying was carried out for 7 minutes. The resulting granules were sieved through a #42 circular sieve (355 ⁇ m) and a #80 circular sieve (177 ⁇ m) to provide 2393 g of powders (177 to 355 ⁇ m) having a core.
  • a centrifugal fluidized coating granulator [manufactured by Powrex Corp. (Japan), MP-10] was charged with 600 g of the above enteric-coated powders having a core. While the inlet air temperature and the outlet air temperature were controlled at 65° C. and 32° C. respectively, a film coating liquid of the following composition prepared in advance was sprayed in accordance with the tangential spray method at the spray rate of 11 g/min. Then, drying was carried out for 7 minutes. 617 g of overcoated enteric-coated powders having a core was obtained.
  • a fluidized bed granulator [manufactured by Powrex Corp. (Japan), LAB-1] was charged with 800 g of mannitol [manufactured by Merck Japan Co., Ltd.], and granulation was carried out while spraying 315 g of purified water. The granules were dried to provide 727.3 g of granulated powders.
  • 250 g of the above mixed powder was tabletted by a pounder (15R, 11 mm in diameter) using a rotary type tabletting machine at the tabletting pressure of 1.5 ton/cm 2 to provide tablets each weighing 500 mg.
  • the hardness and oral disintegration time of each tablet thus obtained were 5.9 kg and 30 seconds respectively.
  • a centrifugal fluidized coating granulator [manufactured by Powrex Corp. (Japan), MP-10 (Type 2)] was charged with 900 g of Nonpareil 105 (trade name) (particle diameter of 100 to 200 ⁇ m). With the inlet air temperature and the temperature of the loading being controlled at 65° C. and about 30° C. respectively, the Nonpareil was coated by spraying a bulk liquid of the following composition prepared in advance in accordance with the tangential spray method at a spray rate of 22 g/min. The spraying operation was stopped when the specified amount 5661 g of the bulk liquid had been sprayed, and then drying was carried out in the granulator for 8 minutes. The resulting granules were sieved through a #42 circular sieve (350 ⁇ m) and a #100 circular sieve (150 ⁇ m) to provide 2074 g of granules having a core.
  • a centrifugal fluidized coating granulator [manufactured by Powrex Corp. (Japan), MP-10 (Type 2)] was charged with 2074 g of the above granules having a core.
  • an undercoating liquid of the following composition prepared in advance was sprayed in accordance with the tangential spray method at a spray rate of 22 g/min.
  • the spraying operation was stopped when the specified amount 1980 g of the undercoating liquid had been sprayed, and then drying was carried out in the granulator for 9 minutes.
  • the resulting granules were sieved through a #42 circular sieve (350 ⁇ m) and a #100 circular sieve (150 ⁇ m) to provide 2555 g of film-undercoated granules having a core.
  • Undercoating Liquid Hydroxypropylmethylcellulose 252 g (Type 2910, viscosity: 3 centistokes) Titanium oxide (TiO 2 ) 108 g Sterilized Talc (trade name) 108 g [produced by Matsumura Sangyo Co. Ltd. (Japan)] Low-substituted hydroxypropyl cellulose LH-32 180 g (hydroxypropoxyl group contents: 8.8 weight %) Mannitol 252 g Purified water 3600 g (3) Production of Enteric Coated Granules Having a Core
  • a centrifugal fluidized coating granulator [manufactured by Powrex Corp. (Japan), MP-10 (Type 2)] was charged with 1320 g of the above film-undercoated granules having a core. With the inlet air temperature and the temperature of the loading being controlled at 80° C. and about 42° C., respectively, an enteric film coating liquid (A) of the following composition prepared in advance was sprayed in accordance with the tangential spray method at a spray rate of 22 g/min. The specified amount 1638 g of the enteric film coating liquid had been sprayed.
  • Enteric Film Coating Liquid (A): Eudragit L30D-55 1219.2 g Eudragit NE30D 134.4 g Polyethylene glycol 6000 40.8 g Glyceryl monostearate 24.0 g Polysorbate 80 7.2 g Ferric oxide 0.24 g Ferric oxide (yellow) 0.24 g Citric acid anhydrous 0.48 g Purified water 1693 g
  • an enteric film coating liquid (B) of the following composition prepared in advance was sprayed in accordance with the tangential spray method at a spray rate of 22 g/min.
  • the specified amount 6552 g of the enteric film coating liquid had been sprayed.
  • Enteric Film Coating Liquid (B): Eudragit L30D-55 4032 g Eudragit NE30D 447.8 g Triethyl citrate 269.3 g Glyceryl monostearate 86.4 g Polysorbate 80 25.9 g Ferric oxide 0.86 g Ferric oxide (yellow) 0.86 g Citric acid anhydrous 0.72 g Purified water 2624 g
  • an enteric film coating liquid (A) of the above mentioned composition prepared in advance was sprayed in accordance with the tangential spray method at a spray rate of 22 g/min.
  • the specified amount 819 g of the enteric film coating liquid had been sprayed.
  • an film coating liquid of the following composition prepared in advance was sprayed in accordance with the tangential spray method at a spray rate of 22 g/min. using a centrifugal fluidized coating granulator [manufactured by Powrex Corp. (Japan), MP-10 (Type 2)].
  • the spraying operation was stopped when the specified amount 882 g of the film coating liquid had been sprayed, and then drying was carried out in the granulator for 10 minutes.
  • the resulting granules were sieved through a #35 circular sieve (420 ⁇ m) and a #60 circular sieve (250 ⁇ m) to provide 1964 g of enteric coated and mannitol coated granules having a core.
  • the average particle diameter of the obtained granules was 333.7 ⁇ m.
  • the hardness and oral disintegration time of each tablet thus obtained were 2.6 kg and 20 seconds, respectively.
  • the acid-resistance of the obtained tablet was 3.5%.
  • a fluidized bed granulator [manufactured by Powrex Corp. (Japan), LAB-1] was charged with 0.6 g of voglibose, 410.4 g of erythritol [manufactured by Nikken Chemicals Co., Ltd. (Japan)], 120.0 g of low-substituted hydroxypropylcellulose LH-33 (content of hydroxypropoxyl group: 5.8% by weight, average particle diameter: 17.8 ⁇ m), 30.0 g of CEOLUS KG-801 [manufactured by Asahi Chemical Industry Co., Ltd.
  • the hardness and oral disintegration time of each tablet thus obtained were 10.7 kg and 26 seconds respectively.
  • a fluidized bed granulator [manufactured by Powrex Corp. (Japan), LAB-1] was charged with 0.6 g of voglibose, 440.4 g of erythritol [manufactured by Nikken Chemicals Co., Ltd. (Japan)], 120.0 g of low-substituted hydroxypropylcellulose LH-33 (content of hydroxypropoxyl group: 5.8% by weight, average particle diameter: 17.8 ⁇ m), 30.0 g of crospovidone, 6.0 g of anhydrous citric acid and 1.2 g of aspartame, and granulation was carried out while spraying purified water. After drying, 1.8 g of magnesium stearate was incorporated. The resulting powder was tabletted by a pounder (beveled edge, 10 mm in diameter) using a rotary type tabletting machine at the tabletting pressure of 1.0 ton/cm 2 to provide tablets each weighing 300 mg.
  • the hardness and oral disintegration time of each tablet thus obtained were 7.1 kg and 20 seconds respectively.
  • a fluidized bed granulator [manufactured by Powrex Corp. (Japan), LAB-1] was charged with 0.4 g of voglibose, 470.6 g of erythritol [manufactured by Nikken Chemicals Co., Ltd. (Japan)], 120.0 g of low-substituted hydroxypropylcellulose LH-33 (content of hydroxypropoxyl group: 5.7% by weight, average particle diameter: 30.8 ⁇ m), 6.0 g of anhydrous citric acid and 1.2 g of aspartame, and granulation was carried out while spraying purified water. After drying, 1.8 g of magnesium stearate was incorporated. The resulting powders was tabletted by a pounder (beveled edge, 10 mm in diameter) using a rotary type tabletting machine at the tabletting pressure of 1.25 ton/cm 2 to provide tablets each weighing 300 mg.
  • the hardness and oral disintegration time of each tablet thus obtained were 4.5 kg and 23 seconds respectively.
  • a fluidized bed granulator [manufactured by Powrex Corp. (Japan), LAB-1] was charged with 0.4 g of voglibose, 470.6 g of mannitol [manufactured by Merck Japan Co., Ltd.], 120.0 g of low-substituted hydroxypropylcellulose LH-23 (content of hydroxypropoxyl group: 5.7% by weight, average particle diameter: 30.8 ⁇ m), 6.0 g of anhydrous citric acid and 1.2 g of aspartame, and granulation was carried out while spraying purified water. After drying, 1.8 g of magnesium stearate was incorporated. The resulting powder was tabletted by a pounder (beveled edge, 10 mm in diameter) using a rotary type tabletting machine at the tabletting pressure of 1.25 ton/cm 2 to provide tablets each weighing 300 mg.
  • the hardness and oral disintegration time of each tablet thus obtained were 4.3 kg and 27 seconds respectively.
  • a fluidized bed granulator [manufactured by Powrex Corp. (Japan), LAB-1] was charged with 40.0 g of manidipine hydrochloride, 460.94 g of erythritol [manufactured by Nikken Chemicals Co., Ltd. (Japan)], 60.0 g of low-substituted hydroxypropylcellulose LH-33 (content of hydroxypropoxyl group: 5.8% by weight, average particle diameter: 17.8 ⁇ m), 30.0 g of crospovidone, 6.0 g of anhydrous citric acid and 1.2 g of aspartame, and granulation was carried out while spraying purified water in which was dissolved 0.06 g of yellow iron oxide.
  • magnesium stearate was incorporated.
  • the resulting powder was tabletted by a pounder (beveled edge, 10 mm in diameter) using a rotary type tabletting machine at the tabletting pressure of 1.0 ton/cm 2 to provide tablets each weighing 300 mg.
  • the hardness and oral disintegration time of each tablet thus obtained were 6.0 kg and 21 seconds respectively.
  • Low-substituted hydroxypropylcellulose LH-30 (content of hydroxypropoxyl group: 14.6% by weight, average particle diameter: 17.26 ⁇ m), LH-31 (content of hydroxypropoxyl group: 11.0% by weight, average particle diameter: 18.18 ⁇ m), LH-32 (content of hydroxypropoxyl group: 8.8% by weight, average particle diameter: 17.57 ⁇ m) and LH-33 (content of hydroxypropoxyl group: 5.8% by weight, average particle diameter: 17.8 ⁇ m) were administered to 4 females respectively, and dissolubility and taste were evaluated.
  • Tablets were produced by using low-substituted hydroxypropylcellulose LH-30 (content of hydroxypropoxyl group: 14.6% by weight, average particle diameter: 17.26 ⁇ m), LH-31 (content of hydroxypropoxyl group: 11.0% by weight, average particle diameter: 18.18 ⁇ m), LH-32 (content of hydroxypropoxyl group: 8.8% by weight, average particle diameter: 17.57 ⁇ m) and LH-33 (content of hydroxypropoxyl group: 5.8% by weight, average particle diameter: 17.8 ⁇ m) in accordance with the following manner.
  • LH-30 content of hydroxypropoxyl group: 14.6% by weight, average particle diameter: 17.26 ⁇ m
  • LH-31 content of hydroxypropoxyl group: 11.0% by weight, average particle diameter: 18.18 ⁇ m
  • LH-32 content of hydroxypropoxyl group: 8.8% by weight, average particle diameter: 17.57 ⁇ m
  • LH-33 content of hydroxypropoxyl group: 5.8% by weight, average particle diameter: 17.
  • a fluidized bed granulator [manufactured by Powrex Corp. (Japan), LAB-1] was charged with 398.5 g of erythritol [manufactured by Nikken Chemicals Co., Ltd. (Japan)] and 100 g of low-substituted hydroxypropylcellulose, and granulation was carried out while spraying purified water. After drying, 1.5 g of magnesium stearate was incorporated. The resulting powder was tabletted by a pounder (beveled edge, 10 mm in diameter) using a rotary type tabletting machine at the tabletting pressure of 1.0 ton/cm 2 to provide tablets each weighing 300 mg.
  • the resulting tablets were administered to 4 females respectively, and dissolubility and taste was evaluated.
  • the rapidly disintegrable solid preparation of the present invention is usable for treatment and prevention of various kinds of diseases especially as the oral rapidly disintegrable solid preparation, which is capable of being administered to elders or children without water, because the preparation has superior disintegrability and dissolubility. It is also improved in its disintegrability in the stomach.
  • the rapidly disintegrable solid preparation has superior long-term stability because the preparation has suitable strength.
  • the rapidly disintegrable solid preparation of the present invention is improved in dissolubility and chalky taste, and has no roughness.

Abstract

A rapidly disintegrable solid preparation which comprises (i) a pharmacologically active ingredient, (ii) a sugar and (iii) a low-substituted hydroxypropylcellulose having 5% by weight or more to less than 7% by weight of hydroxypropoxyl group. The rapidly disintegrable solid preparation has fast disintegrability, suitable strength and no roughness.

Description

    TECHNICAL FIELD
  • The present invention relates to a solid preparation having fast disintegrability in the oral cavity with the existence of saliva, in a little water, or in the stomach particularly a rapidly disintegrable solid preparation which is useful as an orally disintegrable solid preparation.
  • BACKGROUND ART
  • It has been desired to develop an orally disintegrable solid preparation which can be easily administered to elders or children without water. As background arts which disclose such a preparation, for example, there are the following background arts.
  • JP-A-9-48726 discloses an orally rapidly disintegrable preparation produced by wetting in a moldable way on humidifying. It comprises a drug and a material which can retain the shape after molding and drying. As such materials, a sugar, sugar alcohol and a water-soluble polymer material are exemplified.
  • JP-A-9-71523 discloses a tablet containing a drug, crystalline cellulose, a low-substituted hydroxypropylcellulose and a lubricant. It has fast disintegrability in the oral cavity.
  • EP-A 839526 discloses a solid pharmaceutical preparation containing a pharmacologically active ingredient, erythritol, crystalline cellulose and a disintegrator.
  • However, these background arts have not described (i) a pharmacologically active ingredient, (ii) a sugar and (iii) a low-substituted hydroxypropylcellulose having 5% by weight or more to less than 7% by weight of hydroxypropoxyl group of the present invention.
  • DISCLOSURE OF INVENTION
  • There has been desired the development of a rapidly disintegrable solid preparation having fast disintegrability in the existence of saliva in the oral cavity, in a little water or in the stomach, having suitable strength (hardness) so that it may not be damaged through production processes and distribution, and further having no roughness.
  • The present invention relates to:
  • (1) a rapidly disintegrable solid preparation which comprises (i) a pharmacologically active ingredient, (ii) a sugar and (iii) a low-substituted hydroxypropylcellulose having 5% by weight or more to less than 7% by weight of hydroxypropoxyl group;
  • (2) the preparation of the above (1), which is an orally rapidly disintegrable solid preparation;
  • (3) the preparation of the above (1) or (2), which is a tablet;
  • (4) the preparation of the above (1), wherein the sugar is a sugar alcohol;
  • (5) the preparation of the above (4), wherein the sugar alcohol is mannitol or erythritol;
  • (6) the preparation of the above (1), wherein the sugar is comprised in an amount of 5 to 97 parts by weight per 100 parts by weight of the solid preparation;
  • (7) the preparation of the above (1), wherein the low-substituted hydroxypropylcellulose having 5% by weight or more to less than 7% by weight of hydroxypropoxyl group is used in an amount of 3 to 50 parts by weight per 100 parts by weight of the solid preparation;
  • (8) the preparation of the above (1), wherein the pharmacologically active ingredient is lansoprazole;
  • (9) the preparation of the above (1), wherein the pharmacologically active ingredient is voglibose;
  • (10) the preparation of the above (1), wherein the pharmacologically active ingredient is manidipine hydrochloride;
  • (11) the preparation of the above (1), wherein the pharmacologically active ingredient is pioglitazone hydrochloride;
  • (12) the preparation of the above (1), wherein the pharmacologically active ingredient is candesartan cilexetil;
  • (13) the preparation of the above (3) which comprises fine granules;
  • (14) the preparation of the above (13), wherein the pharmacologically active ingredient is comprised in the fine granules.
  • (15) the preparation of the above (14), wherein (i) a sugar and (ii) a low-substituted hydroxypropylcellulose having 5% by weight or more to less than 7% by weight of hydroxypropoxyl group are comprised in the solid preparation separately from the fine granules;
  • (16) the preparation of the above (15), wherein the sugar is in an amount of 5 to 97 parts by weight per 100 parts by weight of the rest of the solid preparation other than the fine granules;
  • (17) the preparation of the above (15), wherein the low-substituted hydroxypropylcellulose having 5% by weight or more to less than 7% by weight of hydroxypropoxyl group is in an amount of 3 to 50 parts by weight per 100 parts by weight of the rest of the solid preparation other than the fine granules;
  • (18) use of a low-substituted hydroxypropylcellulose having 5% by weight or more to less than 7% by weight of hydroxypropoxyl group for producing a rapidly disintegrable solid preparation comprising a pharmacologically active ingredient and a sugar; and
  • (19) a method for improving fast disintegrability of a solid preparation comprising a pharmacologically active ingredient and a sugar, which is characterized in that a low-substituted hydroxypropylcellulose having 5% by weight or more to less than 7% by weight of hydroxypropoxyl group is contained therein.
  • 1) Pharmacologically Active Ingredient
  • The pharmacologically active ingredients used in the present invention are in any condition such as solid, powdery, crystalline, oily and solution conditions. As such pharmacologically active ingredients, for example, one or more ingredient(s) selected from the group comprising nourishing and cordial agents, antipyretic-anodyne-anti-inflammatory drugs, psychotropics, antianxiety drugs, antidepressants, hypnotic-sedative drugs, spasmolytics, central nervous system drugs, brain metabolism ameliorating agents, brain circulation ameliorating agents, antiepileptics, sympathomimetics, gastrointestinal agents, antacids, antiulcer agents, antitussive-expetorants, antiemetics, respiratory accelerators, bronchodilators, antiallergic drugs, dental buccal drugs, antihistamines, cardiotonics, antiarrythmic drugs, diuretics, antihypertensive agents, vasoconstrictors, coronary vasodilators, peripheral vasodilators, antihypolipidemic agents, cholagogues, antibiotics, chemotherapeutic drugs, antidiabetic agents, drugs for osteoporosis, antirheumatism agents, skeletal muscle relaxants, antivertigos, hormones, alkaloid narcotics, sulfa drugs, arthrifuges, blood coagulation inhibitors, antitumor agents, drugs for Alzheimer's disease and the like are exemplified.
  • As the nourishing and cordial agents, for instance, vitamins such as vitamin A, vitamin D, vitamin E (such as d-α-tocopherol acetate and the like), vitamin B1 (such as dibenzoylthiamine, fursultiamine hydrochloride and the like), vitamin B2 (such as riboflavin butyrate and the like), vitamin B6 (such as pyridoxine hydrochloride and the like), vitamin C (such as ascorbic acid, sodium L-ascorbate and the like) and vitamin B12 (such as hydroxocobalamin acetate, cyanocobalamin and the like); minerals such as calcium, magnesium, iron and the like; proteins, amino acids, oligosaccharides, crude drugs and the like are exemplified.
  • As the antipyretic-anodyne-antiinflammatory drugs, for instance, aspirin, acetaminophen, ethenzamide, ibuprofen, diphenhydramine hydrochloride, dl-chlorpheniramine maleate, dihydrocodeine phosphate, noscapine, methylephedrine hydrochloride, phenylpropanolamine hydrochloride, caffeine, anhydrous caffein, serrapeptase, lysozyme chloride, tolfenamic acid, mefenamic acid, sodium diclofenac, flufenamic acid, salicylamide, aminopyrine, ketoprofen, indometacin, bucolome, pentazocine and the like are exemplified.
  • As the antipsychotics, for instance, chlorpromazine, reserpine and the like are exemplified.
  • As the antianxiety drugs, for instance, alprazolam, chlordiazepoxide, diazepam and the like are exemplified.
  • As the antidepressants, for instance, imipramine, maprotiline hydrochloride, amphetamine and the like are exemplified.
  • As the hypnotic-sedative drugs, for instance, estazolam, nitrazepam, diazepam, perlapine, sodium phenobarbital and the like are exemplified.
  • As the spasmolytics, for instance, scopolamine hydrobromide, di-phenhydramine hydrochloride, papaverine hydrochloride and the like are exemplified.
  • As the central nervous system drugs, for instance, citicoline and the like are exemplified.
  • As the brain metabolism ameliorating agents, for instance, meclofenoxate hydrochloride and the like are exemplified.
  • As the brain circulation ameliorating agents, for instance, vinpocetine and the like are exemplified.
  • As the antiepileptics, for instance, phenytoin, carbamazepine and the like are exemplified.
  • As the sympathomimetics, for instance, isoproterenol hydrochloride and the like are exemplified.
  • As the gastrointestinal agents, for instance, stomachic-digestives such as diastase, saccharated pepsin, scopolia extract, cellulase AP3, lipase AP and cinnamon oil; agents for intestinal disorders such as berberine chloride, resistant lactic acid bacterium, Lactobacillus bifidus and the like are exemplified.
  • As the antacids, for instance, magnesium carbonate, sodium hydrogen-carbonate, magnesium aluminometasilicate, synthetic hydrotalcite, precipitated calcium carbonate, magnesium oxide and the like are exemplified.
  • As the antiulcer agents, for instance, lansoprazole, omeprazole, rabeprazole, pantoprazole, famotidine, cimetidine, ranitidine hydrochloride and the like are exemplified.
  • As the antitussive-expetorants, for instance, chloperastine hydrochloride, dextromethorphan hydrobromide, theophylline, potassium guaiacolsulfonate, guaiafenesin, codeine phosphate and the like are exemplified.
  • As the antiemetics, for instance, difenidol hydrochloride, metoclopramide and the like are exemplified.
  • As the respiratory accelerators, for instance, levallorphan tartrate and the like are exemplified.
  • As the bronchodilators, for instance, theophylline, salbutanol sulfate and the like are exemplified.
  • As the antiallergic drugs, for instance, amlexanox, seratrodast and the like are exemplified.
  • As the dental buccal drugs, for instance, oxytetracycline, triamcinolone acetonide, chlorhexidine hydrochloride, lidocaine and the like are exemplified.
  • As the antihistamines, for instance, diphenhydramine hydrochloride, promethazine, isothipendyl hydrochloride, dl-chlorpheniramine maleate and the like are exemplified.
  • As the cardiotonics, for instance, caffeine, digoxin and the like are exemplified.
  • As the antiarrythmic drugs, for instance, procainamide hydrochloride, propranolol hydrochloride, pindolol and the like are exemplified.
  • As the diuretics, for instance, isosorbide, furosemide, thiazides such as HCTZ and the like are exemplified.
  • As the antihypertensive agents, for instance, delapril hydrochloride, captopril, hexamethonium bromide, hydrazine hydrochloride, labetalol hydrochloride, manidipine hydrochloride, candesartan cilexetil, methyldopa, losartan, valsartan, eprosartan, irbesartan, tasosartan, telmisartan, and the like are exemplified.
  • As the vasoconstrictors, for instance, phenylephrine hydrochloride and the like are exemplified.
  • As the coronary vasodilators, for instance, carbocromen hydrochloride, molsidomine, verapamil hydrochloride and the like are exemplified.
  • As the peripheral vasodilators, for instance, cinnarizine and the like are exemplified.
  • As the antihypolipidemic agents, for instance, sodium cerivastatin , simvastatin, sodium pravastatin and the like are exemplified.
  • As the cholagogues, for instance, dehydrocholic acid, trepibutone and the like are exemplified.
  • As the antibiotics, for instance, cephems such as cefalexin, cefaclor, amoxicillin, pivmecillinam hydrochloride, cefotiam hexetyl hydrochloride, cefadroxil, cefixime, cefditoren pivoxil, cefteram pivoxyl, cefpodoxime proxetil, cefotiam dihydrochloride, cefozopran hydrochloride, cefmenoxime hemihydrochloride, sodium cefsulodin; synthetic antibacterial agents such as ampicillin, ciclacillin, sodium sulbenicillin, nalidixic acid and enoxacin; monobactams such as sodium carumonam; penems; carbapenems and the like are exemplified.
  • As the chemotherapeutic drugs, for instance, sulfamethizole, sulfamethizole hydrochloride, thiazosulfone and the like are exemplified.
  • As the antidiabetic agents, for instance, tolbutamide, voglibose, pioglitazone hydrochloride, glibenclamide, troglitazone, rosiglitazone maleate, acarbose, miglitol, emigitate and the like are exemplified.
  • As the drugs for osteoporosis, for instance, ipriflavone and the like are exemplified.
  • As the skeletal muscle relaxants, for instance, methocarbamol and the like are exemplified.
  • As the antivertigos, for instance, meclizine hydrochloride, dimenhydrinate and the like are exemplified.
  • As the antirheumatism agents, for instance, methotrexate, bucillamine, and the like are exemplified.
  • As the hormones, for instance, sodium liothyronine, dexamethasone sodium phosphate, prednisolone, oxendolone, leuprorelin acetate and the like are exemplified.
  • As the alkaloid narcotics, for instance, opium, morphine hydrochloride, ipecac, oxycodone hydrochloride, opium alkaloids hydrochlorides, cocaine hydrochloride and the like are exemplified.
  • As the sulfa drugs, for instance, sulfamine, sulfisomidine, sulfamethizole and the like are exemplified.
  • As the arthrifuges, for instance, allopurinol, colchicine and the like are exemplified.
  • As the blood coagulation inhibitors, for instance, dicoumarol and the like are exemplified.
  • As the antitumor agents, for instance, 5-fluorouracil, uracil, mitomycin and the like are exemplified.
  • As the drugs for Alzheimer's disease, for instance, idebenone, vinpocetine and the like are exemplified.
  • Among the above pharmacologically active ingredients, nourishing and cordial agents, antipyretic-anodyne-antiinflammatory drugs, hypnotic-sedative drugs, central nervous system drugs, gastrointestinal agents, antiulcer agents, antitussive-expetorants, antiallergic drugs, antiarrhythmic drugs, diuretics, antihypertensive agents, vasoconstrictors, coronary vasodilators, antihypolipidemic agents, antidiabetic agents, drugs for osteoporosis, skeletal muscle relaxants, antivertigos and the like are preferably used.
  • In the present invention, the pharmacologically active ingredients preferably used are antiulcer agents such as lansoprazole; antidiabetic agents such as voglibose and pioglitazone hydrochloride; and antihypertensive agents such as manidipine hydrochloride and candesartan cilexetil and the like are exemplified.
  • Two or more pharmacologically active ingredients can be optionally used in an admixture in a rapidly disintegrable solid preparation of this invention.
  • The pharmacologically active ingredient is optionally diluted by the diluents generally used in the fields of medical treatment and food. In addition, it is optionally treated for the purpose of masking the bitterness of the pharmacologically active ingredient.
  • The above pharmacologically active ingredient is used in an amount of, for example, 0.01 to 70 parts by weight, preferably 0.02 to 50 parts by weight, more preferably 0.05 to 30 parts by weight, per 100 parts by weight of the solid preparation.
  • 2) Sugar
  • As the sugars used in the present invention, for example, sugar, starch sugar, lactose, honey and sugar alcohol are exemplified. Such sugars are optionally used in an admixture thereof with suitable ratio.
  • As the sugar, for example, sucrose, coupling sugar, fructo-oligosaccharide, palatinose are exemplified.
  • As the starch sugar, for example, glucose, maltose, powdered sugar, starch syrup, fructose and fruit sugar and the like are exemplified.
  • As the lactose, for example, lactose, isomerized lactose (lactulose), reduced lactose (lactitol) and the like are exemplified.
  • As the honey, various kinds of honey which are generally edible are exemplified.
  • As the sugar alcohol, for example, sorbitol, mannitol, maltitol, reduced starch saccharide, xylitol, reduced paratinose, erythritol, and the like are exemplified. As erythritol is optionally one used which is produced by fermentation using glucose as a starting material with yeast in general and has at most 50 mesh of the particle size. Such erythritol is commercially available [for example, from Nikken Chemicals Co., Ltd. (Japan)].
  • The above sugars are preferably water-soluble sugars. The water-soluble sugars mean any water-soluble sugars which need at most 30 ml of water when 1 g of sugar is added into water and then dissolved within 30 minutes at 20° C. by strongly shaking every 5 minutes for 30 seconds.
  • In the present invention, the sugar is preferably the sugar alcohol, more preferably mannitol or erythritol.
  • In order to obtain sufficient strength of the preparation and sufficiently fast disintegrability, the sugar is used in an amount of 5 to 97 parts by weight, preferably 10 to 90 parts by weight, per 100 parts by weight of the solid preparation in case of the solid preparation not comprising fine granules. On the other hand, the sugar is used in an amount of 5 to 97 parts by weight, preferably 10 to 90 parts by weight, per 100 parts by weight of the rest of the solid preparation other than the fine granules in case of the solid preparation comprising fine granules.
  • For example, mannitol or erythritol is usually used in an amount of 5 to 90 weight %, preferably 10 to 80 weight %, more preferably 20 to 80 weight %, especially preferably 50 to 80 weight % relative to the whole solid preparation in case of the solid preparation not comprising fine granules. On the other hand, mannitol or erythritol is usually used in an amount of 5 to 90 weight %, preferably 10 to 80 weight %, more preferably 20 to 80 weight %, especially preferably 50 to 80 weight % relative to the rest of the solid preparation other than the fine granules in case of the solid preparation comprising fine granules.
  • 3) Low-Substituted Hydroxypropylcellulose Having 5% by Weight or More to Less than 7% by Weight of Hydroxypropoxyl Group (L-HPC) 3-1) Production of L-HPC
  • The “low-substituted hydroxypropylcellulose having 5% by weight or more to less than 7% by weight of hydroxypropoxyl group (hereinafter, optionally referred to L-HPC)” used in the present invention can be produced in accordance with well-known methods, for example, methods described in JP-B-57-53100 or its analogous methods thereof.
  • At first, alkaline cellulose containing free alkaline and propylene oxide are reacted to obtain the crude low-substituted hydroxypropylcellulose containing free alkaline.
  • Concretely, for example, raw material pulp such as wood pulp and cotton leader is immersed in 10 to 50% concentration of aqueous solution of sodium hydroxide, and pressed to obtain the alkaline cellulose of which NaOH/cellulose ratio is 0.1 to 1.2 (ratio by weight). Next, the crude low-substituted hydroxypropylcellulose containing free alkaline is obtained by reacting the resulting alkaline cellulose and propylene oxide with stirring at 20 to 90° C. for 2 to 8 hours. Propylene oxide is used in an amount so that the content of hydroxypropoxyl group in the desired low-substituted hydroxypropylcellulose can be 5% or more by weight to less than 7% by weight.
  • The crude low-substituted hydroxypropylcellulose containing free alkaline is dispersed in water or hot water containing 5 to 80% of acid which is need to neutralize the all amount of alkaline, and a part of the crude low-substituted hydroxypropylcellulose containing free alkaline is dissolved therein. Further, acid is added to neutralize the remained alkaline.
  • After the neutralization, processes such as drainage, drying and grinding are performed in accordance with the conventional method to obtain the desired low-substituted hydroxypropylcellulose.
  • 3-2) Property of L-HPC
  • The particle diameter of L-HPC used in the present invention is, for example, 5 to 60 μm as average particle diameter. Preferably, it is 10 to 40 μm as average particle diameter.
  • In the above ranges, in case that L-HPC having relatively large particle diameter (for example, L-HPC having 26 to 40 μm of average particle diameter) is used, a pharmaceutical preparation being superior in disintegrability can be produced. On the other hand, in case that L-HPC having relatively small particle diameter (for example, L-HPC having 10 to 25 μm of average particle diameter) is used, the pharmaceutical preparation being superior in strength of the preparation can be produced.
  • Accordingly, the particle diameter of L-HPC can be suitably selected according to the character of the desired pharmaceutical preparation.
  • In order to obtain sufficient strength of the preparation and sufficiently fast disintegrability, the L-HPC in the present invention is used in an amount of 3 to 50 parts by weight, preferably 5 to 40 parts by weight, per 100 parts by weight of the solid preparation in case of the solid preparation not comprising fine granules. On the other hand, the L-HPC in the present invention is used in an amount of 3 to 50 parts by weight, preferably 5 to 40 parts by weight, per 100 parts by weight of the rest of the solid preparation other than the fine granules in case of the solid preparation comprising fine granules.
  • As mentioned above, by using L-HPC, it becomes possible to improve fast disintegrability, particularly the orally fast disintegrability, of the solid preparation containing the pharmacologically active ingredient and the sugar.
  • 4) Dosage Forms
  • As the dosage form of the rapidly disintegrable solid preparation of the present invention, for example, tablet, granule, fine granule and the like, preferably tablet is exemplified. Among rapidly disintegrable tablets such as an orally disintegrable tablet and a tablet disintegrable in water, the orally disintegrable tablet is preferable.
  • 5) Other Ingredients
  • Unless fast disintegrability (particularly, fast disintegrability in the oral cavity) or strength of the preparation is interfered with, the rapidly disintegrable solid preparation of the present invention may further contain a variety of additives which are commonly used in the manufacture of preparations in general dosage forms. Amount of such additives to be used is one commonly used in the manufacture of preparations in general dosage forms. As such additives, for example, binders, acids, foaming agents, artificial sweeteners, flavorants, lubricants, colorants, stabilizers, excipients, disintegrators and the like are exemplified.
  • As the above binders, for example, hydroxypropylcellulose, hydroxypropylmethylcellulose, crystalline cellulose, pregelatinized starch, polyvinylpyrrolidone, gum arabic powder, gelatin, pullulan and the like are exemplified. These two or more binders can be used in an admixture in a given ratio. The use of crystalline cellulose as the binder provides the solid preparation which exhibits more excellent strength of the preparation while retaining excellent fast disintegrability in the oral cavity. As the crystalline cellulose, microcrystalline cellulose is also included. The “crystalline cellulose” includes a refined one having partially α-cellulose depolymerization. As crystalline cellulose, for example, CEOLUS KG 801, Avicel PH 101, Avicel PH 102, Avicel PH 301, Avicel PH 302, Avicel RC-A591 NF (crystalline cellulose•carmellose sodium), Avicel RC-591 (crystalline cellulose•carmellose sodium) and the like are concretely exemplified. Among them, CEOLUS KG 801 referred to as highly moldable crystalline cellulose is preferably used. Such crystalline celluloses are optionally used in an admixture thereof with suitable ratio. Such crystalline celluloses can be commercially available (manufactured by Asahi Chemical Industry Co., Ltd. (Japan)). The crystalline cellulose is used in an amount of, for example, 1 to 50 parts by weight, preferably 2 to 40 parts by weight, more preferably 2 to 20 parts by weight, per 100 parts by weight of the solid preparation in case of the solid preparation not comprising fine granules. Likewise, the crystalline cellulose is used in an amount of, for example, 1 to 50 parts by weight, preferably 2 to 40 parts by weight, more preferably 2 to 20 parts by weight, per 100 parts by weight of the solid preparation apart from fine granules in case of the solid preparation comprising fine granules.
  • As the acids, for example, citric acid, tartaric acid, malic acid and the like are exemplified.
  • As the foaming agents, for example, sodium bicarbonate and the like are exemplified.
  • As the artificial sweeteners, for example, saccharin sodium, dipotassium glycyrrhizinate, aspartame, stevia, thaumatin and the like are exemplified.
  • As the flavorants, for example, lemon, lemon lime, orange, mentol, strawberry and the like are exemplified.
  • As the lubricants, for example, magnesium stearate, sucrose fatty acid ester, polyethylene glycol, talc, stearic acid and the like are exemplified. Use of polyethylene glycol as the lubricant provides the stable solid preparation of which the decomposition over time of the pharmacologically active ingredient is controlled. At that time, polyethylene glycol is used in an amount of, for example, 0.01 to 10 parts by weight, preferably 0.1 to 5 parts by weight, per 100 parts by weight of the solid preparation in case of the solid preparation not comprising fine granules. Likewise, polyethylene glycol is used in an amount of, for example, 0.01 to 10 parts by weight, preferably 0.1 to 5 parts by weight, per 100 parts by weight of the solid preparation apart from fine granules in case of the solid preparation comprising fine granules.
  • As the colorants, for example, various food colorants such as Food Yellow No. 5, Food Red No. 2, Food Blue No. 2 and the like; food lakes, red iron oxide and the like are exemplified.
  • As the stabilizers, for example, a basic substance in the case of the basic pharmacologically active ingredient and an acidic substance in the case of the acidic pharmacologically active ingredient are exemplified.
  • As the excipients, for example, lactose, sucrose, D-mannitol, starch, corn starch, crystalline cellulose, light silicic anhydride, titanium oxide and the like are exemplified.
  • As the disintegrators, for example, disintegrators called super disintegrators such as crospovidone [manufactured by ISP Inc. (U.S.A.), BASF (Germany)], croscarmellose sodium [FMC-Asahi Chemical Industry Co., Ltd. (Japan)], carmellose calcium [Gotoku Chemical (Yakuhin), (Japan)]; hydroxypropylcellulose; low-substituted hydroxypropylcellulose; carboxymethylstarch sodium [Matsutani Chemical Co., Ltd. (Japan)]; corn starch and the like are exemplified. Among them, crospovidone is preferably used. Such two or more disintegrators are optionally used in an admixture thereof with suitable ratio.
  • As crospovidone, any cross-linked homopolymer such as 1-ethenyl-2-pyrrolidinone homopolymer may be used, and usually crospovidone having a molecular weight of at least 1,000,000 is used. As crospovidone which is commercially available, for example, Cross-linked povidone, Kollidone CL [manufactured by BASF (Germany)], Polyplasdone XL, Polyplasdone XL-10, INF-10 [manufactured by ISP Inc., (U.S.A.)], polyvinylpolypyrrolidone, PVPP, 1-vinyl-2-pyrrolidinone homopolymer and the like are concretely exemplified.
  • Two or more of these disintegrants can be as a mixture in a given ratio. For example, (i) crospovidone solely, or (ii) crospovidone and another disintegrant(s) is preferably used.
  • Such disintegrator is used in an amount of, for example, 0.1 to 20 parts by weight, preferably 1 to 10 parts by weight, more preferably 3 to 7 parts by weight, per 100 parts by weight of the solid preparation in case of the solid preparation not comprising fine granules. Likewise, such disintegrator is used in an amount of, for example, 0.1 to 20 parts by weight, preferably 1 to 10 parts by weight, more preferably 3 to 7 parts by weight, per 100 parts by weight of the rest of the solid preparation other than the fine granules in case of the solid preparation comprising fine granules.
  • 5-1) Other Ingredients for Dosage Forms, Especially of Acid-Labile Pharmacologically Active Ingredient
  • In case that the pharmacologically active ingredient is an acid-labile one such as lansoprazole, omeprazole, rapeprazole, pantoprazole and the like, a basic inorganic salt is preferably incorporated to stabilize the pharmacologically active ingredient in the solid preparation.
  • The “basic inorganic salt” includes, for example, a basic inorganic salt of sodium, potassium, magnesium and/or calcium, preferably a basic inorganic salt of magnesium and/or calcium. Among others, preferred is a basic inorganic salt of magnesium.
  • The basic inorganic salt of sodium includes, for example, sodium carbonate, sodium hydrogencarbonate, sodium phosphate, sodium hydrogenphosphate and the like.
  • The basic inorganic salt of potassium includes, for example, potassium carbonate, potassium hydrogencarbonate, potassium phosphate, potassium hydrogenphosphate, potassium sodium carbonate and the like.
  • The basic inorganic salt of magnesium includes, for example, heavy magnesium carbonate, magnesium carbonate, magnesium oxide, magnesium hydroxide, magnesium metasilicate aluminate, magnesium silicate aluminate, magnesium silicate, magnesium aluminate, synthetic hydrotalcite [Mg6Al2(OH)16.CO3.4H2O], aluminum magnesium hydroxide [2.5MgO.Al2O3.xH2O] and the like. Among others, preferred is heavy magnesium carbonate, magnesium carbonate, magnesium oxide, magnesium hydroxide and the like.
  • The basic inorganic salt of calcium includes, for example, precipitated calcium carbonate, calcium hydroxide, and the like.
  • The preferable examples of the “basic inorganic salt” are magnesium basic inorganic salt, and more preferable examples include heavy magnesium carbonate, magnesium carbonate, magnesium oxide, magnesium hydroxide, and the like.
  • Such basic inorganic salt of magnesium or calcium, and the like has a basic pH (not less than 7) when it is in the form of a 1% aqueous solution or suspension.
  • Two or more of these basic inorganic salts (preferably a basic inorganic salt of magnesium, a basic inorganic salt of calcium, and the like) can be used as a mixture in a given ratio. The amount of the basic inorganic salt to be used is appropriately selected depending on the kind of the basic inorganic salt and is, for instance, 0.3 to 200 parts by weight, preferably 1 to 100 parts by weight, more preferably 10 to 50 parts by weight, especially preferably 20 to 40 parts by weight relative to the pharmacologically active ingredient.
  • 6) Dosage Form Containing Fine Granules (e.g., Tablet)
  • As was mentioned before, the rapidly disintegrable preparation of the present invention can be used in any solid dosage form such as tablet, granule, fine granule and the like. In case that it is a tablet, the tablet can contain fine granules. The fine granules may contain the pharmacologically active ingredient. These dosage forms can be prepared by a conventional method or its analogous method.
  • 7) Fine Granule Containing Core
  • The fine granule can contain a core together with or separately from the pharmacologically active ingredient. As such a core, for example, (1) a spherical granulated product comprising crystalline cellulose and lactose [e.g., a spherical granulated product being 100 to 200 μm and comprising crystalline cellulose (3 parts) and lactose (7 parts) (Nonpareil 105 (trade name), manufactured by Freund Industrial Co., Ltd. (Japan)), a spherical granulated product being 150 to 250 μm and comprising crystalline cellulose (3 parts) and lactose (7 parts) (Nonpareil NP-7:3 (trade name), manufactured by Freund Industrial Co., Ltd. (Japan), a spherical granulated product being 150 to 250 μm and comprising crystalline cellulose (5 parts) and lactose (5 parts) (Nonpareil NP-5:5 (trade name), manufactured by Freund Industrial Co., Ltd. (Japan)) and the like], (2) a spherical granulated product being 150 to 250 μm and comprising crystalline cellulose [avicel SP (trade name), manufactured by Asahi Chemical Industry Co., Ltd. (Japan) and the like) and the like are exemplified.
  • In case that a core is used, the core is optionally coated with the pharmacologically active ingredient and the like, and further coated for masking taste or smell and/or for imparting enteric dissolubility or sustained-release property by well known methods. In this case, such a core forms a fine granule comprising the pharmacologically active ingredient. As a coating agent in this case, for example, enteric-coated polymers (e.g., cellulose acetate phthalate (CAP), methacrylate copolymer L, methacrylate copolymer LD (Eudragit L30D-55 (trade name; manufactured by Rohm GmbH (Germany))), methacrylate copolymer S, hydroxypropylmethylcellulose phthalate, hydroxymethylcellulose acetate succinate, hydroxypropylmethylcellulose acetate succinate, KolllCoat MAE30DP (trade name; manufactured by BASF (Germany)), Polyquid PA-30 (trade name; manufactured by SanyoKasei (Japan)), carboxymethylethylcellulose, shellac, methacrylate copolymer [e.g., Eudragit NE30D (trade name), Eudragit RL30D (trade name), Eudragit RS30D (trade name) and the like] triethyl citrate, polyethylene glycol, acetylated monoglyceride, triacetin, castor oil, and the like), gastric dissolvable polymers (e.g., polyvinylacetal dietbylaminoacetate, aminoalkyl methacrylate copolymer and the like), water-soluble polymers (e.g., hydroxypropylcellulose, hydroxypropylmethylcellulose and the like), slightly soluble-polymers (e.g., ethylcellulose, aminoalkyl methacrylate copolymer RS, ethyl acrylate methyl methacrylate copolymer and the like), wax and the like are exemplified. One or more kind(s) of coating agents are used in an admixture.
  • 7-1) Production of Fine Granules
  • The “fine granules” in the present invention can be produced by a known granulation method.
  • The “granulation method” includes, for example, rolling granulation method (e.g., centrifugal rolling granulation, etc.), fluidized-bed granulation (e.g., rolling fluidized-bed granulation, fluidized granulation, etc.), stirring granulation and the like. Among others, preferred is fluidized-bed granulation method, more preferred is rolling fluidized-bed granulation method.
  • Concrete example of the “rolling granulation method” includes a method using “CF apparatus” manufactured by Freund Industrial Co., Ltd. (Japan) and the like. Concrete examples of the “rolling fluidized-bed granulation method” include methods using “SPIR-A-FLOW”, “multi plex” manufactured by Powrex Corp. (Japan), “New-Marumerizer” manufactured by Fuji Paudal Co., Ltd. (Japan), and the like. The method for spraying the mixture can be suitably selected in accordance with the kind of granulator, and may be, for example, any one of a top spray method, a bottom spray method, a tangential spray method, and the like. Among others, a tangential spray method is preferred.
  • The “fine granules” in the present invention can be coated with any other ingredient including the active ingredient and the others, by a conventional coating method or its analogous method. For example, a method which comprises coating a core comprising crystalline cellulose and lactose with an acid-labile physiologically active substance is employed in case that pharmacologically active ingredient is an acid-labile physiologically active substance.
  • For example, used is a method described in JP-A-5-92918 (coating method), which comprises coating a core comprising crystalline cellulose and lactose with an acid-labile physiologically active substance, if necessary together with a basic inorganic salt, binders, lubricants, excipients, a water-soluble polymer, etc. (hereinafter, may be abbreviated to “coating layer”). For example, employed is a method which comprises coating a core with an acid-labile physiologically active substance and a basic inorganic salt, and then further with binders, lubricants, excipients, a water-soluble polymer, etc.
  • 7-2) Property of Core for Fine Granules
  • The average particle diameter of the “cores” is 250 μm or less, preferably 50 to 250 μm, more preferably 100 to 250 μm, especially preferably 100 to 200 μm. The “cores” having the above average particle diameter include particles which all pass through a #50 sieve (300 μm), particles where 5 w/w % or less of the total remain on a #60 sieve (250 μm), and particles where 10 w/w % or less of the total pass through a #282 sieve (53 μm). The specific volume of the “core” is 5 ml/g or less, preferably 3 ml/g or less.
  • Examples of the “core” include:
    • (1) a spherical granulated product comprising crystalline cellulose and lactose, (2) a spherical granulated product being 150 to 250 μm and comprising crystalline cellulose (Avicel SP, manufactured by Asahi Chemical Co., Ltd. (Japan)), (3) a stirring granulated product being 50 to 250 μm and comprising lactose (9 parts) and a starch (1 part), (4) a micro particle being 250 μm or less classified as a spherical granule comprising micro crystalline cellulose described in JP-A-61-213201, (5) a processed product such as wax formed to a sphere by spraying or melting granulation, (6) a processed product such as gelatin beads comprising oil component, (7) calcium silicate, (8) starch, (9) a porous particle such as chitin, cellulose, chitosan, etc, and (10) a bulk product such as granulated sugar, crystalline lactose or sodium chloride, and processed preparations thereof. Further, these cores may be produced in accordance with per se known grinding method or granulation method, and sifted to prepare the particles having the desired particle diameter.
  • The above “spherical granulated product comprising crystalline cellulose and lactose” includes, for example (i) a spherical granulated product being 100 to 200 μm and comprising crystalline cellulose (3 parts) and lactose (7 parts) [e.g., Nonpareil 105 (70-140) (particle diameter of 100 to 200 μm), manufactured by Freund Industrial Co., Ltd. (Japan)], (ii) a spherical granulated product being 150 to 250 μm and comprising crystalline cellulose (3 parts) and lactose (7 parts) [e.g., Nonpareil NP-7:3, manufactured by Freund Industrial Co., Ltd. (Japan)], (iii) a spherical granulated product being 100 to 200 μm and comprising crystalline cellulose (4.5 parts) and lactose (5.5 parts) [e.g., Nonpareil 105T (70-140) (particle diameter of 100 to 200 μm), manufactured by Freund Industrial Co., Ltd. (Japan)], (iv) a spherical granulated product being 150 to 250 μm and comprising crystalline cellulose (5 parts) and lactose (5 parts) [e.g., Nonpareil NP-5:5, manufactured by Freund Industrial Co., Ltd. (Japan)], and the like.
  • In order to produce a pharmaceutical preparation which is superior in dissolution while retaining suitable strength, the “core” includes, for example, preferably the spherical granulated product comprising crystalline cellulose and lactose, more preferably the spherical granulated material comprising crystalline cellulose and lactose and containing 50 weight % or more of lactose relative to the whole solid preparation. Among others, preferred is a core comprising 40 to 50 weight % of crystalline cellulose and 50 to 60 weight % of lactose.
  • As the “core” employed in the present invention, preferably, there may be employed the spherical granulated product comprising crystalline cellulose and lactose, more preferably the spherical granulated product with a diameter of 100 to 200 μm and comprising crystalline cellulose (4.5 parts) and lactose (5.5 parts).
  • The “core” may contain the physiologically active substance such as the above described pharmacologically active ingredient. Also, the “core” may not contain the physiologically active substance because the release of the physiologically active substance can be controlled by a coating layer containing the physiologically active substance.
  • The “core” is preferably as uniform a sphere as possible, for reducing the irregularity of the coating, in addition to being a powdery core.
  • The ratio of the “coating layer” to the “core” can be selected within the range in which it is possible to control dissolution of the physiologically active substance and particle size of the composition, for example, usually 50 to 400 parts by weight relative to 100 parts by weight of the core.
  • 7-3) Coating Method of Fine Granules
  • The coating layer may be constructed by plural layers. At least one layer of the plural layers must contain the physiologically active substance. The combination of various layers such as a coating layer not containing the active ingredient, a base coating layer, and an enteric coating layer which constitute the coating layer can be suitably selected.
  • In case that the “core” is coated, for example, the above physiologically active substance and the water-soluble polymer can be employed in an admixture thereof. The admixture may be a solution or a dispersion, and can be prepared by using an organic solvent such as water or ethanol or an admixture thereof.
  • The concentration of the water-soluble polymer in the admixture varies according to the ratio of the physiologically active substance and the additives, and is usually 0.1 to 50 weight %, preferably 0.5 to 10 weight % relative to the whole solid preparation, in order to retain the binding strength of the physiologically active substance to the core and maintain the viscosity of the mixture so as not to reduce the workability.
  • Where the coating layer comprises plural layers, the concentration of the physiologically active substance in each layer may be changed successively or gradually by selecting for the content ratio or viscosity of the water-soluble polymer or by successive coating with mixtures varying in the ratio of the physiologically active substance and the other additives. In the above case, it may be coated with a mixture in which the content ratio of the water-soluble polymer is out of the range of 0.1 to 50 weight %, as long as the coating layer as a whole contains 0.1 to 50 weight % of the water-soluble polymer. Further, in forming the inactive coat according to known methods, the coating layer optionally comprises some layers such that the inactive layer may block each layer containing the physiologically active substance.
  • Also, in case of two or more physiologically active substances not suited in the compatibility, the core may be coated by employing each mixture together or separately.
  • The above coated material is dried, and passed through sieves to obtain a “composition” having uniform size. Because the form of the composition is usually according to the core, a fine granule being in the form of a rough sphere can be obtained. As the sieve may be employed, for example a #50 circular sieve (300 μm). The composition is obtained by selecting those which pass through the #50 circular sieve.
  • The “fine granule” in the present invention can be produced in accordance with in the same manner as above granulation method, for example, a method which comprises coating the composition with an enteric coating layer, in order to protect the physiologically active substance or to impart enteric dissolution. If necessary, the composition coated with an enteric coating layer may be further coated by a water-soluble sugar alcohol, preferably mannitol. In such case, the strength of the orally disintegrable tablet comprising fine granules is improved.
  • The “enteric coating layer” is preferably a layer having 20 to 70 μm, preferably 30 to 50 μm of thickness and coating the whole surface of the composition containing the physiologically active substance. Accordingly, the smaller particle diameter of the composition, the higher the weight % of the enteric coating layer in the whole fine granule. In the fine granule of the present invention, the “enteric coating layer” is 30 to 70 weight %, preferably 50 to 70 weight %, of the fine granule as a whole.
  • The “enteric coating layer” are optionally constructed by plural (e.g., 2 or 3) layers. For example, the used is a method which comprises coating a composition with an enteric coating layer having polyethyleneglycol, and then with an enteric coating layer having triethyl citrate, followed by being coated with an enteric coating layer having polyethyleneglycol.
  • 8) Production of Rapidly Disintegrable Solid Preparation
  • The rapidly disintegrable solid preparation of the present invention can be produced in accordance with a conventional method or its analogous method in the field of pharmaceutical preparation. As such method, for example, a method comprising blending the pharmacologically active ingredient, the sugar and the low-substituted hydroxypropylcellulose having 5% by weight or more to less than 7% by weight of hydroxypropoxyl group after adding water if needed, molding, and then drying if needed is exemplified. However, the rapidly disintegrable solid preparation of the present invention can be produced also without water.
  • 8-1) Production of Rapidly Disintegrable Tablet
  • For the production of the orally disintegrable tablet, a conventional molding method or its analogous method can be applied by using appropriate ingredients selected from the above-mentioned ones including the fine granules.
  • Preferred example of the method for the orally disintegrable tablet having the fine granules of the coated cores comprises:
    • (i) coating a core comprising crystalline cellulose and lactose with a physiologically active substance and an excipient, followed by being coated with a coating layer comprising a water-soluble polymer to obtain a composition,
    • (ii) coating the resultant composition with an enteric coating layer having polyethyleneglycol, and then with an enteric coating layer having triethyl citrate, and then followed by being coated by mannitol to obtain fine granule, and
    • (iii) blending the resultant fine granule with an additive, followed by molding.
  • The molding procedure can be carried out, for instance, by tabletting with a pressure of 0.5 to 3 ton/cm2, preferably 1 to 2 ton/cm2 by using a single-punch tabletting machine [Kikusui Seisakusho (Japan)] or a rotary type tabletting machine [Kikusui Seisakusho (Japan)] when a solid preparation is a tablet, especially an orally disintegrable tablet.
  • The drying procedure can be carried out by any techniques such as vacuum drying, fluidized-bed drying and the like used to dry the general pharmaceutical preparation.
  • The blending procedure can be carried out by any conventional blending techniques such as admixing, kneading, granulating and the like. The blending procedure is carried out by using an apparatus such as Vertical Granulator VG10 [manufactured by Powrex Corp. (Japan)], Universal Kneader [manufactured by Hata Iron Works Co., Ltd. (Japan)], fluidized bed granulator LAB-1 and FD-3S [manufactured by Powrex Corp. (Japan)], centrifugal fluidized coating granulator MP-10, MP-400 [manufactured by Powrex Corp. (Japan)] and the like.
  • In the present specification, “coating” means also partial coating and adhesion or adsorption in addition to coating the whole surface of an object (e.g., core) which is to be coated.
  • “Spherical” means also forms having a curved surface such as forms having elliptic cross sections, and forms in the shapes of eggplants and drops in addition to spheres.
  • “Average particle diameter” means volume based distribution median diameter (median diameter: 50% particle diameter from cumulative distribution), unless otherwise specified. It can be measured by, for example, a laser diffraction particle distribution measurement method. Concretely exemplified is a method using Raiser Diffraction Analyzer, type: HEROS RODOS [trade name; manufactured by Sympatec (Germany)].
  • In the present invention, “fine granules” have an average particle diameter of about 400 μm or less, in order that roughness is not felt in the mouth. Preferably, the average particle diameter of the fine granules is 300 to 400 mm.
  • Aside from the average particle diameter of the above “fine granules”, regarding the maximum particle size, the particle diameter is substantially 425 μm or less, and preferably substantially 400 μm or less. Preferably, the particle diameter is substantially 300 to 425 μm, more preferably 300 to 400 μm.
  • “Substantially” as used in the phases of “the particle diameter is substantially 425 μm or less” and “the particle diameter is substantially 400 μm or less” means that the particles may include a small quantity (about 5 weight % or less) of particles whose particle diameter is out of the above described range, to include the inevitable contaminant particles.
  • The “composition” may contain water-soluble polymers, the above binders, lubricants, excipients and the like in common use as pharmaceutical materials. The amount of such water-soluble polymers, binders, lubricants, and excipients is selected from amounts commonly employed in the manufacture of preparations in general dosage forms.
  • The “water-soluble polymer” includes, for example, a water-soluble polymer which is soluble in ethanol (i.e., an ethanol-soluble water-soluble polymer) such as a cellulose derivative (e.g., hydroxypropyl cellulose, which may be referred to as “HPC” hereinafter), polyvinylpyrrolidone, etc.; a water-soluble polymer which is insoluble in ethanol (i.e., an ethanol-insoluble water-soluble polymer) such as a cellulose derivative (e.g., hydroxypropylmethyl cellulose, which may be referred to as “HPMC” hereinafter, methyl cellulose, carboxymethyl cellulose sodium, etc.), sodium polyacrylate, polyvinyl alcohol, sodium alginate, and guar gum, etc.
  • When such water-soluble polymers are used, the dissolution of drugs (physiologically active substances) can be controlled by employing them in combination with the ethanol-soluble water-soluble polymer and ethanol-insoluble water-soluble polymer or by employing them in combination with some water-soluble polymers having different viscosity.
  • In the present invention, the “water-soluble polymer” is preferably, a cellulose derivative such as HPC, HPMC, and methyl cellulose, and polyvinyl alcohol. More preferred is a cellulose derivative such as HPC, HPMC.
  • The “HPC” contains, for example, about 53.4 to 77.5 weight %, more preferably about 60 to 70 weight %, of hydroxypropoxyl group. The viscosity of 2 weight % aqueous solution of HPC at 20° C. is usually about 1 to 150,000 cps (centipoise). As the above HPC, hydroxypropyl cellulose defined in Japanese Pharmacopoeia may be employed. Hereinafter, all viscosity of HPC is a value of 2 weight % aqueous solution at 20° C.
  • The “HPMC” is a mixed ether which is connected by a methoxy group and a hydroxypropoxy group. The content of the methoxy group of HPMC is, for example, about 19 to 30 weight %. The content of the hydroxypropoxy group is, for example, about 4 to 12 weight %. The viscosity of 2 weight % aqueous solution of HPMC at 20° C. is usually about 1 to 40,000 centistokes. As such HPMC may be employed hydroxypropylmethyl cellulose 2208 defined by Japanese Pharmacopoeia, hydroxypropylmethyl cellulose 2906 defined by Japanese Pharmacopoeia, hydroxypropylmethyl cellulose 2910 defined by Japanese Pharmacopoeia, and so forth. Hydroxypropyl cellulose(s) may be employed alone or in an admixture of two or more thereof.
  • The content of the water-soluble polymer such as HPC and/or HPMC is usually about 0.1 to 50 weight %, preferably about 1 to 30 weight %, as against the whole “composition” containing the physiologically active substance, in order to control the dissolution of the physiologically active substance in the composition containing the physiologically active substance and retain a high content of the physiologically active substance.
  • In the present invention, the “fine granules” may contain, for example, titanium oxide as a masking agent.
  • The diameter of the “orally disintegrable tablet” of the present invention is about 5 to 20 mm, preferably about 7 to 15 mm, more preferably about 8 to 13 mm.
  • The “orally disintegrable tablet” optionally may not comprise lubricant inside the tablet.
  • When the “fine granule” of the present invention is used for a tablet except for an orally disintegrable tablet, the diameter of the tablet is about 5 to 10 mm, preferably about 5 to 8 mm. When the fine granule of the present invention is used for a capsule, the size of the capsule is preferably a #2 capsule or less.
  • 9) Property of Rapidly Disintegrable Solid Preparation
  • The rapidly disintegrable solid preparation of the present invention thus obtained exhibits fast disintegrability or dissolubility in the oral cavity, water or stomach, and suitable strength of the preparation. Further the rapidly disintegrable solid preparation of the present invention is improved in chalky taste and has no roughness.
  • 9-1) Disintegration Time
  • The orally disintegration time of the rapidly disintegrable solid preparation of the present invention (the time for healthy male or female adults to complete disintegration by buccal saliva) is usually 5 to 50 seconds, preferably 5 to 40 seconds, more preferably 5 to 35 seconds.
  • The disintegration time in the stomach of the rapidly disintegrable solid preparation of the present invention (the time for healthy male or female adults to complete disintegration) is shorter than that of the normal preparation such as a normal tablet.
  • The disintegration time of the rapidly disintegrable solid preparation of the present invention in water is usually 5 to 40 seconds, preferably 5 to 30 seconds, more preferably 5 to 25 seconds.
  • 9-2) Strength of Preparation
  • The strength of the rapidly disintegrable solid preparation of the present invention (measurement with a tablet hardness tester) is usually 2 to 20 kg, preferably 4 to 15 kg.
  • 9-3) Administration Manner
  • The rapidly disintegrable solid preparation of the invention is especially used for an orally disintegrable tablet and can be administered without water or together with water.
  • As administration methods, there are listed (1) a method of administration by dissolution or disintegration together with a little water, or without water and with saliva in the oral cavity, not to be swallowed as it is, or (2) a method of administration with water, where it is swallowed as it is. Also, the tablet may be administered dissolved or disintegrated with water.
  • The “orally disintegrable tablet” of the present invention is advantageously used in (a) cases where administration without water is necessary, (b) cases of administration to a patients who have difficulty in swallowing tablets, or (c) cases of administration to the aged or to children where there is a fear of blocking the throat if it is in usual tablet form.
  • The rapidly disintegrable solid preparation of the present invention can be safely administered orally to mammals such as mouse, rat, rabbit, cat, dog, bovine, horse, monkey, human and the like.
  • 9-4) Dose and Specific Embodiments
  • While the dosage amount of the rapidly disintegrable solid preparation varies depending on a pharmacologically active ingredient, a subject, a kind of disease and the like, the dosage amount is selected so that the dosage amount of the pharmacologically active ingredient can be an effective amount.
  • In case of the above (a), the orally disintegrable tablet is preferably used for antipyretic agents, analgesic agents, anti-inflammatory agents, antianxiety drugs, antitussive-expectorants, anti motion sickness agents, drugs for prevention and treatment for car-sickness, and the like.
  • In case of the above (b), the orally disintegrable tablet is preferably used for preventing and/or treating hypertension, hyperlipemia, diabetes, bronchial asthma, cerebrovascular diseases, and the like.
  • 9-4-1) Lansoprazole
  • For instance, when lansoprazole is used as the pharmacologically active ingredient, the rapidly disintegrable solid preparation of the present invention is useful for treatment and prevention of digestive ulcer (such as gastric ulcer, duodenal ulcer, anastomic ulcer, Zollinger-Ellison syndrome), gastritis, reflex esophagitis and the like; eradication of H. pylori; suppression of upper gastrointestinal bleeding caused by digestive ulcer, acute stress ulcer and hemorrhagic gastritis; suppression of upper gastrointestinal bleeding caused by invasive stress (such as stress caused by a large-scale operation necessitating the following intensive management or cerebrovascular disease, head injury, failure of many organs, burn injury of a wide range which necessitate intensive care); treatment and prevention of ulcer caused by non-steroidal anti-inflammatory agent; treatment and prevention of gastric hyperacidity and ulcer caused by postoperative stress; administration before anesthesia and the like. The dosage amount of the preparation per an adult (body weight: 60 kg) is 0.5 to 1500 mg/day, preferably 5 to 150 mg/day, as lansoprazole.
  • 9-4-2) Voglibose
  • When voglibose is used as the pharmacologically active ingredient, the rapidly disintegrable solid preparation of the present invention is useful for treatment and prevention of obesity, adiposis, lipemia, diabetes mellitus and the like. The dosage amount of the preparation per an adult (body weight: 60 kg) is 0.01 to 30 mg/day, preferably 0.1 to 3 mg/day, as voglibose. The rapidly disintegrable solid preparation can be administered once a day, or 2 to 3 times separately a day.
  • 9-4-3) Manidipine.HCI
  • When manidipine hydrochloride is used as the pharmacologically active ingredient, the rapidly disintegrable solid preparation of the present invention is useful for treatment and prevention of circulatory system diseases such as hypertension, ischemic heart disease (e.g., angina pectori, myocardial infarction and the like), cerebral and peripheral circulatory disorders (e.g., cerebral infarction, transient ischemic attack, constriction of renal artery and the like) and the like. The dosage amount of the preparation per an adult (body weight: 60 kg) is 1 to 200 mg/day, preferably 10 to 20 mg/day, as manidipine hydrochloride. The rapidly disintegrable solid preparation is usually administered once a day after breakrapidly.
  • 9-4-4) Pioglitazone.HCI
  • When pioglitazone hydrochloride is used as the pharmacologically active ingredient, the rapidly disintegrable solid preparation of the present invention is useful as the insulin resistance improving agent and the like, and for treatment and prevention of diabetes mellitus. The dosage amount of the preparation per an adult (body weight: 60 kg) is 7.5 to 60 mg/day, preferably 15 to 45 mg/day, as pioglitazone hydrochloride. The rapidly disintegrable solid preparation can be administered once a day, or 2 to 3 times separately a day.
  • 9-4-5) Candesartan Cilexetil
  • Further, when candesartan cilexetil is used as the pharmacologically active ingredient, the rapidly disintegrable solid preparation of the present invention is useful for treatment and prevention of hypertension, heart diseases, cerebral apoplexy, renal diseases and the like. The dosage amount of the preparation per an adult (body weight: 60 kg) is 1 to 50 mg/day, preferably 2 to 30 mg/day, as candesartan cilexetil.
  • BEST MODE FOR CARRYING OUT THE INVENTION
  • The present invention is more specifically explained by means of the following Reference Examples, Examples and Test Examples. It is to be understood that the present invention is not limited to these Examples.
  • Unless otherwise specifically indicated, the following “%” means % by weight.
  • Also, the content of hydroxypropoxyl group is measured in accordance with the methods described in Japanese Pharmacopoeia (e.g., 13th edition). The physical properties (hardness and disintegration time) of the tablets were determined by the following test methods.
  • (1) Hardness Test
  • Determination was carried out with a tablet hardness tester [manufactured by Toyama Sangyo Co. Ltd. (Japan)]. The test was performed in 10 runs and mean values were shown.
  • (2) Oral Disintegration Time
  • Time for complete disintegration or dissolution of the tablets only by saliva in the oral cavity was determined.
  • EXAMPLES Reference Example 1
  • An alkaline cellulose comprising 24.1% of NaOH, 1.7% of Na2CO3, 42.9% of cellulose, 31.8% of H2O was obtained by immersing wood pulp in 49% aqueous solution of sodium hydroxide and then by pressing it. A reactor was charged with 100 parts by weight of the alkaline cellulose. Then, nitrogen gas replacement was carried out. After the replacement, 5 parts by weight of propylene oxide was charged in the reactor and reacted with stirring at 40° C. for 1 hour, at 50° C. for 1 hour and at 70° C. for 1 hour to provide 103 parts by weight of a reactant.
  • On the other hand, a kneader was charged with 2.5 parts by weight of hot water at 65° C. and 0.13 parts by weight of glacial acetic acid (40% by weight against equivalent for neutralization, initial neutralized acid) and therein, 1 part by weight of the above resulting alkaline cellulose was dispersed. Then, the temperature was adjusted at 30° C. to dissolve a part of the reactant, and 0.20 part by weight of glacial acetic acid (remain of equivalent for neutralization, complete neutralized acid) to provide a processed fiber product containing a part of dissolution and a part of deposit.
  • The resulting product was washed with hot water at 80° C., drained, dried, ground by means of high rolling impact grinder, and sifted by means of a 100 mesh sieve to provide the powder of low-substituted hydroxypropylcellulose LH-33 (content of hydroxypropoxyl group: 5.8% by weight, average particle diameter: 17.8 μm).
  • Reference Example 2
  • Powders of low-substituted hydroxypropylcellulose LH-23, which have a little bigger average particle diameter (content of hydroxypropyl group: 5.7% by weight, average particle diameter: 30.8 μm) were obtained in the same manner as in Reference Example 1.
  • Example 1
  • (1) Production of Powders Having a Core
  • A centrifugal fluidized coating granulator [manufactured by Powrex Corp. (Japan), MP-10] was charged with 900 g of Nonpareil 105 (trade name) (particle diameter: 100 to 200 μm). While the inlet air temperature and the outlet air temperature were controlled at 70° C. and 30° C. respectively, the Nonpareil was coated by spraying a spray liquid of the following composition prepared in advance in accordance with the tangential spray method at the spray rate of 22 g/min. Then, drying was carried out for 10 minutes. The resulting granules were sieved through a #60 circular sieve (250 μm) and a #100 circular sieve (150 μm) to provide 2186 g of powders (150 to 250 μm) having a core.
  • [Spray Liquid]
    Lansoprazole 927 g
    Magnesium carbonate 309 g
    Low-substituted hydroxypropylcellulose LH-32 154.5 g
    (Content of hydroxypropyl group: 8.8% by weight)
    (Average particle diameter: 17.57 μm)
    Hydroxypropylcellulose (Type SSL) 309 g
    Purified water 3955 g

    (2) Production of Film-Undercoated Powders Having a Core
  • A centrifugal fluidized coating granulator [manufactured by Powrex Corp. (Japan), MP-10] was charged with 2040 g of the above powders having a core. While the inlet air temperature and the outlet air temperature were controlled at 75° C. and 40° C. respectively, an undercoating liquid of the following composition prepared in advance was sprayed in accordance with the tangential spray method at the spray rate of 13 g/min. 2145 g of film-undercoated powders having a core was obtained.
  • [Undercoating Liquid]
    Hydroxypropylmethylcellulose  264 g
    (Type 2910, viscosity: 3 centistokes)
    Purified water 5016 g

    (3) Production of Enteric-Coated Powders Having a Core
  • A centrifugal fluidized coating granulator [manufactured by Powrex Corp. (Japan), MP-10] was charged with 1710 g of the above film-undercoated powders having a core. While the inlet air temperature and the outlet air temperature were controlled at 70° C. and 40° C. respectively, an enteric film coating liquid of the following composition prepared in advance was sprayed in accordance with the tangential spray method at the spray rate of 19 g/min. Then, drying was carried out for 7 minutes. The resulting granules were sieved through a #42 circular sieve (355 μm) and a #80 circular sieve (177 μm) to provide 2393 g of powders (177 to 355 μm) having a core.
  • [Enteric Film Coating Liquid]
    Eudragit L30D-55 5016.4 g
    Eudragit NE30D 559.0 g
    Triethyl citrate 333.7 g
    Glyceryl monostearate 106.5 g
    Polysorbate 80 34.8 g
    Red iron oxide 1.8 g
    Purified water 2547.1 g

    (4) Production of Mannitol-Overcoated Enteric-Coated Powders Having a Core
  • A centrifugal fluidized coating granulator [manufactured by Powrex Corp. (Japan), MP-10] was charged with 600 g of the above enteric-coated powders having a core. While the inlet air temperature and the outlet air temperature were controlled at 65° C. and 32° C. respectively, a film coating liquid of the following composition prepared in advance was sprayed in accordance with the tangential spray method at the spray rate of 11 g/min. Then, drying was carried out for 7 minutes. 617 g of overcoated enteric-coated powders having a core was obtained.
  • [Film Coating Liquid]
    Mannitol  33 g
    Purified water 297 g

    (5) Production of Mannitol Granulated Powders
  • A fluidized bed granulator [manufactured by Powrex Corp. (Japan), LAB-1] was charged with 800 g of mannitol [manufactured by Merck Japan Co., Ltd.], and granulation was carried out while spraying 315 g of purified water. The granules were dried to provide 727.3 g of granulated powders.
  • (6) Production of Mixed Powders
  • To 105 g of the above overcoated enteric-coated powders having a core were added 97.3 g of the above mannitol-granulated powders, 15.0 g of low-substituted hydroxypropyl cellulose LH-33 (content of hydroxypropoxyl group: 5.8% by weight, average particle diameter: 17.8 μm), 22.5 g of crystalline cellulose [CEOLUS KG-801 (trade name), manufactured by Asahi Chemical Industry Co., Ltd. (Japan)], 7.5 g of crospovidone, 1.5 g of anhydrous citric acid, 0.45 g of aspartame and 0.75 g of magnesium stearate, which were admixed in a bag to give mixed powders.
  • (7) Production of Orally Disintegrable Tablets
  • 250 g of the above mixed powder was tabletted by a pounder (15R, 11 mm in diameter) using a rotary type tabletting machine at the tabletting pressure of 1.5 ton/cm2 to provide tablets each weighing 500 mg.
  • The hardness and oral disintegration time of each tablet thus obtained were 5.9 kg and 30 seconds respectively.
  • Example 2
  • (1) Production of Granules Having a Core
  • A centrifugal fluidized coating granulator [manufactured by Powrex Corp. (Japan), MP-10 (Type 2)] was charged with 900 g of Nonpareil 105 (trade name) (particle diameter of 100 to 200 μm). With the inlet air temperature and the temperature of the loading being controlled at 65° C. and about 30° C. respectively, the Nonpareil was coated by spraying a bulk liquid of the following composition prepared in advance in accordance with the tangential spray method at a spray rate of 22 g/min. The spraying operation was stopped when the specified amount 5661 g of the bulk liquid had been sprayed, and then drying was carried out in the granulator for 8 minutes. The resulting granules were sieved through a #42 circular sieve (350 μm) and a #100 circular sieve (150 μm) to provide 2074 g of granules having a core.
  • Bulk Liquid:
    Lansoprazole 1080 g
    Magnesium carbonate 360 g
    Low-substituted hydroxypropyl cellulose LH-32 180 g
    (hydroxypropoxyl group contents: 8.8 weight %)
    Hydroxypropyl cellulose (Type SSL) 360 g
    Purified water 4680 g

    (2) Production of Film-Undercoated Granules Having a Core
  • A centrifugal fluidized coating granulator [manufactured by Powrex Corp. (Japan), MP-10 (Type 2)] was charged with 2074 g of the above granules having a core. With the inlet air temperature and the temperature of the loading being controlled at 78° C. and about 40° C., respectively, an undercoating liquid of the following composition prepared in advance was sprayed in accordance with the tangential spray method at a spray rate of 22 g/min. The spraying operation was stopped when the specified amount 1980 g of the undercoating liquid had been sprayed, and then drying was carried out in the granulator for 9 minutes. The resulting granules were sieved through a #42 circular sieve (350 μm) and a #100 circular sieve (150 μm) to provide 2555 g of film-undercoated granules having a core.
  • Undercoating Liquid:
    Hydroxypropylmethylcellulose 252 g
    (Type 2910, viscosity: 3 centistokes)
    Titanium oxide (TiO2) 108 g
    Sterilized Talc (trade name) 108 g
    [produced by Matsumura Sangyo Co. Ltd. (Japan)]
    Low-substituted hydroxypropyl cellulose LH-32 180 g
    (hydroxypropoxyl group contents: 8.8 weight %)
    Mannitol 252 g
    Purified water 3600 g 

    (3) Production of Enteric Coated Granules Having a Core
  • A centrifugal fluidized coating granulator [manufactured by Powrex Corp. (Japan), MP-10 (Type 2)] was charged with 1320 g of the above film-undercoated granules having a core. With the inlet air temperature and the temperature of the loading being controlled at 80° C. and about 42° C., respectively, an enteric film coating liquid (A) of the following composition prepared in advance was sprayed in accordance with the tangential spray method at a spray rate of 22 g/min. The specified amount 1638 g of the enteric film coating liquid had been sprayed.
  • Enteric Film Coating Liquid (A):
    Eudragit L30D-55 1219.2 g
    Eudragit NE30D 134.4 g
    Polyethylene glycol 6000 40.8 g
    Glyceryl monostearate 24.0 g
    Polysorbate 80 7.2 g
    Ferric oxide 0.24 g
    Ferric oxide (yellow) 0.24 g
    Citric acid anhydrous 0.48 g
    Purified water 1693 g
  • Following this, with the inlet air temperature and the temperature of the loading being controlled at 76° C. and about 42° C., respectively, an enteric film coating liquid (B) of the following composition prepared in advance was sprayed in accordance with the tangential spray method at a spray rate of 22 g/min. The specified amount 6552 g of the enteric film coating liquid had been sprayed.
  • Enteric Film Coating Liquid (B):
    Eudragit L30D-55 4032 g
    Eudragit NE30D 447.8 g
    Triethyl citrate 269.3 g
    Glyceryl monostearate 86.4 g
    Polysorbate 80 25.9 g
    Ferric oxide 0.86 g
    Ferric oxide (yellow) 0.86 g
    Citric acid anhydrous 0.72 g
    Purified water 2624 g
  • Following this, with the inlet air temperature and the temperature of the loading being controlled at 80° C. and about 42° C., respectively, an enteric film coating liquid (A) of the above mentioned composition prepared in advance was sprayed in accordance with the tangential spray method at a spray rate of 22 g/min. The specified amount 819 g of the enteric film coating liquid had been sprayed.
  • (4) Production of Enteric Coated and Mannitol Coated Granules Having a Core
  • Following (3), with the inlet air temperature and the temperature of the loading being controlled at 85° C. and about 35° C., respectively, an film coating liquid of the following composition prepared in advance was sprayed in accordance with the tangential spray method at a spray rate of 22 g/min. using a centrifugal fluidized coating granulator [manufactured by Powrex Corp. (Japan), MP-10 (Type 2)]. The spraying operation was stopped when the specified amount 882 g of the film coating liquid had been sprayed, and then drying was carried out in the granulator for 10 minutes. The resulting granules were sieved through a #35 circular sieve (420 μm) and a #60 circular sieve (250 μm) to provide 1964 g of enteric coated and mannitol coated granules having a core.
  • The average particle diameter of the obtained granules was 333.7 μm.
  • Film Coating Liquid:
    Mannitol  180 g
    Purified water 1080 g

    (5) Production of Mixed Powders
  • To 270 g of the above enteric coated and mannitol coated granules having a core were added 204.0 g of mannitol, 30 g of low-substituted hydroxypropyl cellulose LH-33 (hydroxypropoxyl group contents: 5.8 weight %), 30 g of crystalline cellulose [CEOLUS KG-801 (trade name), manufactured by Asahi Chemical Co., Ltd. (Japan)], 15 g of crospovidone, 3 g of citric acid anhydrous, 9 g of aspartame, 6 g of magnesium stearate and 3 g of flavor [STRAWBERRY DURAROME (trade name), manufactured by Nihon Filmenich Co., Ltd. (Japan)], which was admixed in a bag to give mixed powders.
  • (6) Production of Orally Disintegrable Tablets
  • 570 g of the above mixed powders were tabletted using Autograph (trade name; compressing force measurement apparatus) with a punch having a beveled edge, 13 mm in diameter, at a tabletting pressure of 1.5 ton/cm2, to provide tablets each weighing 570 mg.
  • The hardness and oral disintegration time of each tablet thus obtained were 2.6 kg and 20 seconds, respectively.
  • The acid-resistance of the obtained tablet was 3.5%.
  • Example 3
  • A fluidized bed granulator [manufactured by Powrex Corp. (Japan), LAB-1] was charged with 0.6 g of voglibose, 410.4 g of erythritol [manufactured by Nikken Chemicals Co., Ltd. (Japan)], 120.0 g of low-substituted hydroxypropylcellulose LH-33 (content of hydroxypropoxyl group: 5.8% by weight, average particle diameter: 17.8 μm), 30.0 g of CEOLUS KG-801 [manufactured by Asahi Chemical Industry Co., Ltd. (Japan)], 30 g of crospovidone, 6.0 g of anhydrous citric acid and 1.2 g of aspartame, and granulation was carried out while spraying purified water. After drying, 1.8 g of magnesium stearate was incorporated. The resulting powder was tabletted by a pounder (beveled edge, 10 mm in diameter) using a rotary type tabletting machine at the tabletting pressure of 1.0 ton/cm2 to provide tablets each weighing 300 mg.
  • The hardness and oral disintegration time of each tablet thus obtained were 10.7 kg and 26 seconds respectively.
  • Example 4
  • A fluidized bed granulator [manufactured by Powrex Corp. (Japan), LAB-1] was charged with 0.6 g of voglibose, 440.4 g of erythritol [manufactured by Nikken Chemicals Co., Ltd. (Japan)], 120.0 g of low-substituted hydroxypropylcellulose LH-33 (content of hydroxypropoxyl group: 5.8% by weight, average particle diameter: 17.8 μm), 30.0 g of crospovidone, 6.0 g of anhydrous citric acid and 1.2 g of aspartame, and granulation was carried out while spraying purified water. After drying, 1.8 g of magnesium stearate was incorporated. The resulting powder was tabletted by a pounder (beveled edge, 10 mm in diameter) using a rotary type tabletting machine at the tabletting pressure of 1.0 ton/cm2 to provide tablets each weighing 300 mg.
  • The hardness and oral disintegration time of each tablet thus obtained were 7.1 kg and 20 seconds respectively.
  • Example 5
  • A fluidized bed granulator [manufactured by Powrex Corp. (Japan), LAB-1] was charged with 0.4 g of voglibose, 470.6 g of erythritol [manufactured by Nikken Chemicals Co., Ltd. (Japan)], 120.0 g of low-substituted hydroxypropylcellulose LH-33 (content of hydroxypropoxyl group: 5.7% by weight, average particle diameter: 30.8 μm), 6.0 g of anhydrous citric acid and 1.2 g of aspartame, and granulation was carried out while spraying purified water. After drying, 1.8 g of magnesium stearate was incorporated. The resulting powders was tabletted by a pounder (beveled edge, 10 mm in diameter) using a rotary type tabletting machine at the tabletting pressure of 1.25 ton/cm2 to provide tablets each weighing 300 mg.
  • The hardness and oral disintegration time of each tablet thus obtained were 4.5 kg and 23 seconds respectively.
  • Example 6
  • A fluidized bed granulator [manufactured by Powrex Corp. (Japan), LAB-1] was charged with 0.4 g of voglibose, 470.6 g of mannitol [manufactured by Merck Japan Co., Ltd.], 120.0 g of low-substituted hydroxypropylcellulose LH-23 (content of hydroxypropoxyl group: 5.7% by weight, average particle diameter: 30.8 μm), 6.0 g of anhydrous citric acid and 1.2 g of aspartame, and granulation was carried out while spraying purified water. After drying, 1.8 g of magnesium stearate was incorporated. The resulting powder was tabletted by a pounder (beveled edge, 10 mm in diameter) using a rotary type tabletting machine at the tabletting pressure of 1.25 ton/cm2 to provide tablets each weighing 300 mg.
  • The hardness and oral disintegration time of each tablet thus obtained were 4.3 kg and 27 seconds respectively.
  • Example 7
  • A fluidized bed granulator [manufactured by Powrex Corp. (Japan), LAB-1] was charged with 40.0 g of manidipine hydrochloride, 460.94 g of erythritol [manufactured by Nikken Chemicals Co., Ltd. (Japan)], 60.0 g of low-substituted hydroxypropylcellulose LH-33 (content of hydroxypropoxyl group: 5.8% by weight, average particle diameter: 17.8 μm), 30.0 g of crospovidone, 6.0 g of anhydrous citric acid and 1.2 g of aspartame, and granulation was carried out while spraying purified water in which was dissolved 0.06 g of yellow iron oxide. After drying, 1.8 g of magnesium stearate was incorporated. The resulting powder was tabletted by a pounder (beveled edge, 10 mm in diameter) using a rotary type tabletting machine at the tabletting pressure of 1.0 ton/cm2 to provide tablets each weighing 300 mg.
  • The hardness and oral disintegration time of each tablet thus obtained were 6.0 kg and 21 seconds respectively.
  • Test Example 1
  • Low-substituted hydroxypropylcellulose LH-30 (content of hydroxypropoxyl group: 14.6% by weight, average particle diameter: 17.26 μm), LH-31 (content of hydroxypropoxyl group: 11.0% by weight, average particle diameter: 18.18 μm), LH-32 (content of hydroxypropoxyl group: 8.8% by weight, average particle diameter: 17.57 μm) and LH-33 (content of hydroxypropoxyl group: 5.8% by weight, average particle diameter: 17.8 μm) were administered to 4 females respectively, and dissolubility and taste were evaluated.
  • The results are shown in [Table 1].
    TABLE 1
    Low-substituted Trial
    hydroxypropylcellulose subject Evaluation
    LH-30 4/4 difficult of dissolution in the oral
    cavity
    LH-31 4/4 dissolved in the oral cavity, chalky
    taste
    LH-32 4/4 dissolved in the oral cavity, chalky
    taste
    LH-33 4/4 dissolved in the oral cavity, no
    chalky taste
  • As shown in [Table 1], dissolubility and chalky taste are improved, and further no roughness was felt, with respect to the case of low-substituted hydroxypropylcellulose LH-33 comprising 5.8% by weight of hydroxypropoxyl group.
  • Test Example 2
  • Tablets were produced by using low-substituted hydroxypropylcellulose LH-30 (content of hydroxypropoxyl group: 14.6% by weight, average particle diameter: 17.26 μm), LH-31 (content of hydroxypropoxyl group: 11.0% by weight, average particle diameter: 18.18 μm), LH-32 (content of hydroxypropoxyl group: 8.8% by weight, average particle diameter: 17.57 μm) and LH-33 (content of hydroxypropoxyl group: 5.8% by weight, average particle diameter: 17.8 μm) in accordance with the following manner.
  • A fluidized bed granulator [manufactured by Powrex Corp. (Japan), LAB-1] was charged with 398.5 g of erythritol [manufactured by Nikken Chemicals Co., Ltd. (Japan)] and 100 g of low-substituted hydroxypropylcellulose, and granulation was carried out while spraying purified water. After drying, 1.5 g of magnesium stearate was incorporated. The resulting powder was tabletted by a pounder (beveled edge, 10 mm in diameter) using a rotary type tabletting machine at the tabletting pressure of 1.0 ton/cm2 to provide tablets each weighing 300 mg.
  • The resulting tablets were administered to 4 females respectively, and dissolubility and taste was evaluated.
  • The results are shown in [Table 2].
    TABLE 2
    Low-substituted Trial
    hydroxypropylcellulose subject Evaluation
    LH-30 4/4 not dissolved in the oral cavity
    LH-31 4/4 not dissolved in the oral cavity
    LH-32 4/4 felt adhesiveness in the oral cavity,
    still chalky taste after dissolution
    LH-33 4/4 rapidly dissolved in the oral cavity,
    a little chalky taste
  • As shown in [Table 2], dissolubility and chalky taste are improved, and further no roughness was felt, with respect to the case of low-substituted hydroxypropylcellulose LH-33 comprising 5.8% by weight of hydroxypropoxyl group.
  • Effects of Invention
  • The rapidly disintegrable solid preparation of the present invention is usable for treatment and prevention of various kinds of diseases especially as the oral rapidly disintegrable solid preparation, which is capable of being administered to elders or children without water, because the preparation has superior disintegrability and dissolubility. It is also improved in its disintegrability in the stomach.
  • And, the rapidly disintegrable solid preparation has superior long-term stability because the preparation has suitable strength.
  • Further, the rapidly disintegrable solid preparation of the present invention is improved in dissolubility and chalky taste, and has no roughness.

Claims (17)

1. An orally rapidly disintegrable solid preparation which comprises (i) a pharmacologically active ingredient, (ii) a sugar and (iii) a low-substituted hydroxypropylcellulose having 5% by weight or more to less than 7% by weight of hydroxypropoxyl group; wherein said solid preparation is bucally dissolved in from about 5 to about 50 seconds.
2. (canceled)
3. A preparation of claim 1, which is a tablet.
4. A preparation of claim 1, wherein the sugar is a sugar alcohol.
5. A preparation of claim 4, wherein the sugar alcohol is mannitol or erythritol.
6. A preparation of claim 1, wherein the sugar is in an amount of 5 to 97 parts by weight per 100 parts by weight of the solid preparation.
7. A preparation of claim 1, wherein the low-substituted hydroxypropylcellulose having 5% by weight or more to less than 7% by weight of hydroxypropoxyl group is used in an amount of 3 to 50 parts by weight per 100 parts by weight of the solid preparation.
8. (canceled)
9. A preparation of claim 1, wherein the pharmacologically active ingredient is voglibose.
10-11. (canceled)
12. A preparation of claim 1, wherein the pharmacologically active ingredient is candesartan cilexetil.
13. A preparation of claim 3 which comprises fine granules.
14. A preparation of claim 13, wherein the pharmacologically active ingredient is comprised in fine granules of the solid preparation.
15. A preparation of claim 14, wherein (i) a sugar and (ii) a low-substituted hydroxypropylcellulose having 5% by weight or more to less than 7% by weight of hydroxypropoxyl group are comprised in the solid preparation separately from fine granules.
16. A preparation of claim 15, wherein the sugar is in an amount of 5 to 97 parts by weight per 100 parts by weight of the rest of the solid preparation other than the fine granules.
17. A preparation of claim 15, wherein the low-substituted hydroxypropylcellulose having 5% by weight or more to less than 7% by weight of hydroxypropoxyl group is in an amount of 3 to 50 parts by weight per 100 parts by weight of the rest of the solid preparation other than the fine granules.
18-19. (canceled)
US11/403,799 1998-07-28 1999-07-27 Rapidly disintegrable solid preparation Abandoned US20060182802A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/403,799 US20060182802A1 (en) 1998-07-28 1999-07-27 Rapidly disintegrable solid preparation

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP21304998 1998-07-28
JP10-213049 1998-07-28
US11/403,799 US20060182802A1 (en) 1998-07-28 1999-07-27 Rapidly disintegrable solid preparation
PCT/JP1999/004015 WO2000006126A1 (en) 1998-07-28 1999-07-27 Rapidly disintegrable solid preparation
US09/403,429 US7399485B1 (en) 1998-07-28 1999-07-27 Rapidly Disintegrable solid preparation
US09/800,839 US7070805B2 (en) 1998-07-28 2001-03-07 Rapidly disintegrable solid preparation

Publications (1)

Publication Number Publication Date
US20060182802A1 true US20060182802A1 (en) 2006-08-17

Family

ID=16632688

Family Applications (4)

Application Number Title Priority Date Filing Date
US11/403,799 Abandoned US20060182802A1 (en) 1998-07-28 1999-07-27 Rapidly disintegrable solid preparation
US09/403,429 Expired - Fee Related US7399485B1 (en) 1998-07-28 1999-07-27 Rapidly Disintegrable solid preparation
US09/800,839 Expired - Fee Related US7070805B2 (en) 1998-07-28 2001-03-07 Rapidly disintegrable solid preparation
US11/823,603 Abandoned US20070254031A1 (en) 1998-07-28 2007-06-28 Rapidly disintegrable solid preparation

Family Applications After (3)

Application Number Title Priority Date Filing Date
US09/403,429 Expired - Fee Related US7399485B1 (en) 1998-07-28 1999-07-27 Rapidly Disintegrable solid preparation
US09/800,839 Expired - Fee Related US7070805B2 (en) 1998-07-28 2001-03-07 Rapidly disintegrable solid preparation
US11/823,603 Abandoned US20070254031A1 (en) 1998-07-28 2007-06-28 Rapidly disintegrable solid preparation

Country Status (20)

Country Link
US (4) US20060182802A1 (en)
EP (2) EP1100469B1 (en)
JP (3) JP3404648B2 (en)
KR (1) KR100536783B1 (en)
CN (1) CN1149077C (en)
AR (2) AR019935A1 (en)
AT (2) ATE291418T1 (en)
AU (1) AU4802099A (en)
CA (3) CA2338792C (en)
CY (1) CY1110988T1 (en)
DE (2) DE69942777D1 (en)
DK (2) DK1561458T3 (en)
ES (2) ES2237121T3 (en)
HK (2) HK1035501A1 (en)
MY (2) MY151098A (en)
PT (2) PT1100469E (en)
SI (1) SI1100469T1 (en)
TW (2) TW585786B (en)
WO (1) WO2000006126A1 (en)
ZA (1) ZA200100285B (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080152779A1 (en) * 2005-04-15 2008-06-26 Evelyne De Groote Instant Product
US20090155360A1 (en) * 2007-12-10 2009-06-18 Venkatesh Gopi M Orally disintegrating tablets comprising diphenhydramine
US20090202516A1 (en) * 2008-02-08 2009-08-13 Prothera, Inc. Inhibition and treatment of gastrointestinal biofilms
ES2328438A1 (en) * 2007-11-23 2009-11-12 Chiesi Farmaceutici S.P.A. Procedure to determine the polymorphic purity of minidipin dichlorhydrate (Machine-translation by Google Translate, not legally binding)
US20100034891A1 (en) * 2006-04-27 2010-02-11 Takeda Pharmaceutical Company Limited Taste-masking solid preparation of pioglitazone
US20110230656A1 (en) * 2010-03-18 2011-09-22 Shin-Etsu Chemical Co., Ltd. Low-Substituted Hydroxypropylcellulose and Solid Preparation Comprising the Same
US9850512B2 (en) 2013-03-15 2017-12-26 The Research Foundation For The State University Of New York Hydrolysis of cellulosic fines in primary clarified sludge of paper mills and the addition of a surfactant to increase the yield
US9951363B2 (en) 2014-03-14 2018-04-24 The Research Foundation for the State University of New York College of Environmental Science and Forestry Enzymatic hydrolysis of old corrugated cardboard (OCC) fines from recycled linerboard mill waste rejects

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2263660T3 (en) 1998-05-18 2018-01-02 Takeda Pharmaceuticals Co Orally disintegrating tablets.
DK1561458T3 (en) * 1998-07-28 2010-10-25 Takeda Pharmaceutical Fast decaying solid
JP2001058944A (en) * 1999-06-18 2001-03-06 Takeda Chem Ind Ltd Rapidly disintegrating solid formulation
AU5248900A (en) 1999-06-18 2001-01-09 Takeda Chemical Industries Ltd. Quickly disintegrating solid preparations
DE60110666T2 (en) 2000-03-17 2006-02-02 Shin-Etsu Chemical Co., Ltd. Solid preparation containing low-substituted hydroxypropyl cellulose and preparation process
AU4278301A (en) * 2000-03-27 2001-10-08 Kyowa Hakko Kogyo Co. Ltd. Easy-to-take granule
AU2001248751A1 (en) * 2000-04-12 2001-10-23 Banyu Pharmaceutical Co. Ltd. Compositions disintegrating in oral cavity and preparations disintegrating in oral cavity
US6316029B1 (en) * 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
JP4840549B2 (en) * 2000-11-20 2011-12-21 トーアエイヨー株式会社 Stable vasodilator and method for producing the same
PT1341528E (en) * 2000-12-07 2012-03-20 Nycomed Gmbh Rapidly disintegrating tablet comprising an acid-labile active ingredient
US20030224047A1 (en) * 2001-02-15 2003-12-04 Franz G. Andrew Levothyroxine compositions and methods
CA2437754C (en) * 2001-02-15 2010-05-18 Tanabe Seiyaku Co., Ltd. Tablets quickly disintegrated in oral cavity
WO2002092058A1 (en) * 2001-05-15 2002-11-21 Takeda Chemical Industries, Ltd. Rapidly disintegratable solid preparation
US8765176B2 (en) 2001-06-20 2014-07-01 Takeda Pharmaceutical Campany Limited Method of manufacturing tablet
US7105178B2 (en) 2001-07-17 2006-09-12 Sun Pharmaceutical Industries Limited Cardiotonic composition
EP1430888A1 (en) * 2001-09-28 2004-06-23 Sanwa Kagaku Kenkyusho Co., Ltd. Press-coated molded article undergoing quick disintegration
US8105626B2 (en) 2001-10-17 2012-01-31 Takeda Pharmaceutical Company Limited Granules containing acid-unstable chemical in large amount
EP1444978A1 (en) * 2001-11-13 2004-08-11 Kyowa Hakko Kogyo Co., Ltd. Amino acid-containing tablets quickly disintegrating in the oral cavity and process for producing the same
JP2003238393A (en) * 2002-02-15 2003-08-27 Otsuka Pharmaceut Co Ltd Tablet with improved tableting property and method for producing the same
US20030181488A1 (en) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
DE10209982A1 (en) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Dosage form to be administered orally for poorly soluble basic active ingredients
CO5400144A1 (en) * 2002-03-11 2004-05-31 Novartis Ag ORGANIC COMPOUNDS
JP4776229B2 (en) * 2002-07-16 2011-09-21 エラン ファーマ インターナショナル,リミティド Stable nanoparticulate active substance liquid dosage composition
US20040018990A1 (en) * 2002-07-25 2004-01-29 Harvey Rosner Treatment of obesity
BRPI0314932B8 (en) * 2002-10-02 2021-05-25 Meiji Seika Pharma Co Ltd pharmaceutical composition comprising amorphous cefditoren pivoxil and a sucrose ester fatty acid
UA80991C2 (en) 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
CA2502219C (en) 2002-10-16 2012-05-29 Takeda Pharmaceutical Company Limited A process for producing an amorphous isomer of lansoprazole
JP4493970B2 (en) * 2002-10-16 2010-06-30 武田薬品工業株式会社 Sustained formulation
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
EP1759692A3 (en) * 2003-03-10 2007-09-12 Novartis AG Taste-masked solid veterinary compositions
WO2004080439A1 (en) 2003-03-12 2004-09-23 Takeda Pharmaceutical Company Limited Drug composition having active ingredient adhered at high concentration to spherical core
CA2528249C (en) 2003-06-06 2013-03-05 Ethypharm Orally-dispersible multilayer tablet
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
JP2006528181A (en) * 2003-07-18 2006-12-14 サンタラス インコーポレイティッド Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US7838029B1 (en) 2003-07-31 2010-11-23 Watson Laboratories, Inc. Mirtazapine solid dosage forms
JP4601271B2 (en) * 2003-08-01 2010-12-22 大洋薬品工業株式会社 COMPRESSION MOLDING AND METHOD FOR PRODUCING THE SAME
WO2005013964A1 (en) * 2003-08-08 2005-02-17 Ajinomoto Co., Inc. Pharmaceutical preparation containing nateglinide
ATE495746T1 (en) 2003-11-14 2011-02-15 Ajinomoto Kk SOLID DISPERSION OR MEDICAL SOLID DISPERSION PREPARATION OF A PHENYLALANINE DERIVATIVE
JP4767492B2 (en) * 2003-12-25 2011-09-07 ライオン株式会社 Method for producing polymer-coated particles, polymer-coated particles, and compression molded products using the same
US7670624B2 (en) 2004-01-29 2010-03-02 Astella Pharma Inc. Gastrointestinal-specific multiple drug release system
US20050249806A1 (en) * 2004-02-10 2005-11-10 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory drug
WO2005084648A1 (en) * 2004-02-27 2005-09-15 Ranbaxy Laboratories Limited Pharmaceutical compositions comprising candesartan cilexetil
MXPA06011820A (en) * 2004-04-16 2006-12-15 Santarus Inc Combination of proton pump inhibitor, buffering agent, and prokinetic agent.
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2005118166A2 (en) 2004-06-04 2005-12-15 Teva Pharmaceutical Industries, Ltd. Pharmaceutical composition containing irbesartan
US20080102133A1 (en) * 2004-10-05 2008-05-01 Antje Brueck-Scheffler Oral Pharmaceutical Preparation for Proton Pump Antagonists
JP4509118B2 (en) * 2004-10-06 2010-07-21 エルメッド エーザイ株式会社 PHARMACEUTICAL COMPOSITION AND METHOD FOR PRODUCING THE SAME, AND METHOD FOR STABILIZING DIHYDROPYRIDINE COMPOUNDS
WO2006076097A2 (en) * 2004-12-07 2006-07-20 Nektar Therapeutics Stable non-crystalline formulation comprising losartan
JP2008528456A (en) * 2005-01-26 2008-07-31 レツク・フアーマシユーテイカルズ・デー・デー Novel pharmaceutical composition comprising candesartan cilexetil as lipophilic crystalline substance
US20100016378A1 (en) * 2005-04-28 2010-01-21 Toshio Suzuki Method of preventing dihydropyridine compound from degradation
US20070082048A1 (en) * 2005-06-08 2007-04-12 Ronald Warner Sleep aid formulations
WO2006132440A1 (en) * 2005-06-09 2006-12-14 Takeda Pharmaceutical Company Limited Solid preparation
KR100730393B1 (en) * 2005-06-10 2007-06-20 한국콜마 주식회사 Manufacturing method of pharmaceutical composition containing ibuprofen and arginine
JP4739340B2 (en) * 2005-07-22 2011-08-03 田辺三菱製薬株式会社 Orally disintegrating tablets
ES2371414T3 (en) * 2005-07-25 2012-01-02 Otsuka Pharmaceutical Co., Ltd. ORAL PREPARATION TO MEASURE THE METABOLIC CAPACITY OF PYRIMIDINE.
WO2007016948A1 (en) * 2005-08-10 2007-02-15 Add Advanced Drug Delivery Technologies Ltd. Oral preparation with controlled release
EP1934201A1 (en) * 2005-10-06 2008-06-25 Auspex Pharmaceuticals Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
US7811604B1 (en) 2005-11-14 2010-10-12 Barr Laboratories, Inc. Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same
PE20070698A1 (en) * 2005-11-14 2007-08-17 Teijin Pharma Ltd INTRAORAL RAPID DISGREGATION TABLET CONTAINING AMBROXOL HYDROCHLORIDE
JP5209492B2 (en) * 2005-12-21 2013-06-12 ビーエーエスエフ ソシエタス・ヨーロピア Pharmaceutical formulations for the production of fast-disintegrating tablets
GEP20115245B (en) 2005-12-22 2011-06-27 Takeda Pharmaceutical Solid preparation
CA2634232C (en) 2005-12-28 2013-08-20 Takeda Pharmaceutical Company Limited Method of producing solid preparation disintegrating in the oral cavity
WO2007074909A1 (en) 2005-12-28 2007-07-05 Takeda Pharmaceutical Company Limited Controlled release solid preparation
JP3884056B1 (en) * 2006-01-27 2007-02-21 秋山錠剤株式会社 Method for producing intraoral rapidly disintegrating tablet
DE102006006588A1 (en) * 2006-02-13 2007-08-16 Ratiopharm Gmbh Fast-release irbesartan-containing pharmaceutical composition
CA2650498A1 (en) * 2006-03-31 2007-10-11 Rubicon Research Private Limited Orally disintegrating tablets
CA2649262A1 (en) * 2006-04-13 2007-10-25 Otsuka Pharmaceutical Co., Ltd. Test agent for diagnosing dyspepsia
TWI494134B (en) * 2006-06-20 2015-08-01 Siegfried Generics Int Ag Composition granule and tablet containing candesartan cilexetil and process to fabricate the tablet
EP2043613A1 (en) * 2006-07-14 2009-04-08 Fmc Corporation Solid form
DE602007005653D1 (en) 2006-08-04 2010-05-12 Ethypharm Sa MULTILAYER MOUTH-CATCHING TABLET
KR101445757B1 (en) 2006-08-04 2014-10-02 에씨팜 Granule and orally disintegrating tablet comprising oxycodone
US20080031944A1 (en) * 2006-08-04 2008-02-07 Cima Labs Inc. Stabilization of lorazepam
BG109687A (en) * 2006-09-26 2008-03-31 Иван ХРИСТОВ Antiasthmatic drug
WO2008068727A2 (en) * 2006-12-06 2008-06-12 Ranbaxy Laboratories Limited Pharmaceutical composition comprising candesartan cilexetil
EP2101738A2 (en) * 2006-12-21 2009-09-23 Mallinckrodt Inc. Composition of and method for preparing orally disintegrating tablets
TWI488658B (en) * 2006-12-26 2015-06-21 Daiichi Sankyo Co Ltd Method for improvement of elution
EP2098250B1 (en) * 2006-12-28 2016-09-28 Takeda Pharmaceutical Company Limited Orally disintegrating solid preparation
US20080181932A1 (en) * 2007-01-30 2008-07-31 Drugtech Corporation Compositions for oral delivery of pharmaceuticals
JP3967767B1 (en) * 2007-02-08 2007-08-29 秋山錠剤株式会社 Method for producing intraoral rapidly disintegrating tablet
RU2478375C2 (en) 2007-03-13 2013-04-10 ДАЙНИППОН СУМИТОМО ФАРМА Ко., ЛТД. Tablet, which is decomposed in mouth
WO2008112388A1 (en) 2007-03-14 2008-09-18 Drugtech Corporation Spatial arrangement of particles in a drinking device for oral delivery of pharmaceuticals
US20080311162A1 (en) * 2007-05-16 2008-12-18 Olivia Darmuzey Solid form
CN102046147B (en) * 2007-06-06 2013-03-20 巴斯夫欧洲公司 Pharmaceutical formulation for the production of rapidly disintegrating tablets
US10406105B2 (en) * 2007-06-06 2019-09-10 Basf Se Pharmaceutical formulation for the production of rapidly disintegrating tablets
US20100184785A1 (en) * 2007-06-06 2010-07-22 Basf Se Pharmaceutical formulation for the production of chewable tablets and lozenges
JP2010529071A (en) * 2007-06-06 2010-08-26 ビーエーエスエフ ソシエタス・ヨーロピア Pharmaceutical formulations for the production of fast-disintegrating tablets
WO2009022670A1 (en) * 2007-08-10 2009-02-19 Takeda Pharmaceutical Company Limited Quickly disintegrating tablet
US8323695B2 (en) * 2007-08-13 2012-12-04 Mcneil-Ppc, Inc. Method for stabilizing phenylephrine
EP2196221A4 (en) * 2007-09-27 2011-12-28 Mitsubishi Tanabe Pharma Corp Rapidly disintegrating solid preparation
DE102007052070A1 (en) 2007-10-30 2009-05-07 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg candesartancilexetil
JP5352474B2 (en) * 2007-12-28 2013-11-27 沢井製薬株式会社 Orally disintegrating tablet and method for producing the same
AR070863A1 (en) 2008-03-11 2010-05-12 Takeda Pharmaceutical SOLID PREPARATION OF ORAL DISINTEGRATION AND METHOD TO SUPPRESS THE RUPTURE OF FINE GRANULES DURING PRODUCTION OF A TABLET
EP3031451B1 (en) 2009-01-26 2018-03-07 Shin-Etsu Chemical Co., Ltd Wet granulation tableting method using aqueous dispersion of low-substituted hydroxypropyl cellulose
US10653235B2 (en) * 2009-07-08 2020-05-19 Wayne R Solan Toothpaste droplets
GB201003734D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Delayed prolonged drug delivery
GB201003731D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery
CN102970996A (en) * 2010-05-25 2013-03-13 大卫·科索尔 Compositions and methods for reduction of mercury toxicity
WO2012014052A2 (en) * 2010-07-30 2012-02-02 Micro Labs Limited Novel coated extended release pharmaceutical compositions containing paliperidone
CN102379854A (en) * 2010-08-31 2012-03-21 扬子江药业集团北京海燕药业有限公司 Manidipine hydrochloride oral quick release preparation and preparation method thereof
US8623978B2 (en) 2010-11-23 2014-01-07 Basf Se Process for the preparation of low-peroxide crosslinked vinyllactam polymer
JP2011046750A (en) * 2010-12-09 2011-03-10 Mitsubishi Tanabe Pharma Corp Quickly disintegrating tablet in oral cavity
PE20141115A1 (en) 2010-12-27 2014-09-12 Takeda Pharmaceutical ORAL DISINTEGRATION TABLET
JP2012162467A (en) * 2011-02-04 2012-08-30 Sawai Pharmaceutical Co Ltd Method for producing candesartan cilexetil-containing granule and method for producing candesartan cilexetil-containing tablet
US9023931B2 (en) 2011-04-12 2015-05-05 Basf Se Oxidation-sensitive, low-peroxide polymer comprising at least one inorganic phosphorus compound
DE202011005055U1 (en) 2011-04-12 2011-09-12 Basf Se Low-peroxide polymer containing phosphorus compound
EP2511331A1 (en) 2011-04-12 2012-10-17 Basf Se Low peroxide phosphorous compound contained polymers
DE112012001679B4 (en) 2011-04-12 2023-05-04 Basf Se Sealed packaging form filled with protective gas, containing an oxidation-sensitive, low-peroxide polymer, its use and method for stabilizing oxidation-sensitive polymers against peroxide formation
WO2013081563A2 (en) 2011-10-24 2013-06-06 Mahmut Bilgic Stable tablet formulations
JP5925318B2 (en) 2011-11-30 2016-05-25 武田薬品工業株式会社 Dry-coated tablets
EP2887066B1 (en) 2012-08-20 2020-08-05 Otsuka Pharmaceutical Co., Ltd. Composition for use in a method for measuring carbohydrate metabolism ability
JP6379043B2 (en) * 2013-01-30 2018-08-22 沢井製薬株式会社 Pharmaceutical composition containing candesartan cilexetil
KR20210014204A (en) 2013-03-15 2021-02-08 오츠카 세이야쿠 가부시키가이샤 Method of measuring insulin resistance with fatty acid combustion, and composition used herein
KR101847947B1 (en) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 Stabilized modified release vitamin d formulation
CN105392486A (en) 2013-05-21 2016-03-09 武田药品工业株式会社 Orally disintegrable tablet
JP6238921B2 (en) * 2014-02-17 2017-11-29 大原薬品工業株式会社 Tablets containing irbesartan
EP3204495B1 (en) * 2014-10-08 2020-04-22 Synthetic Biologics, Inc. Beta-lactamase formulations and uses thereof
JP6340325B2 (en) * 2014-12-29 2018-06-06 沢井製薬株式会社 Naphtopidil-containing orally disintegrating tablets
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
US9744135B2 (en) 2015-02-27 2017-08-29 Deseret Laboratories, Inc. Fast disintegrating compositions and tablets thereof
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
JP7198575B2 (en) * 2017-07-11 2023-01-04 キョーリンリメディオ株式会社 Orally disintegrating tablet containing memantine hydrochloride
FR3099881B1 (en) 2019-08-13 2022-08-26 Ethypharm Sa Low dosage opioid orodispersible tablet and process for its preparation.
CN111012755A (en) * 2020-01-09 2020-04-17 仁和堂药业有限公司 Preparation process of vitamin B6 tablets
JP2022140430A (en) * 2021-03-10 2022-09-26 日本ジェネリック株式会社 Rivaroxaban-containing tablet

Citations (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4371516A (en) * 1976-10-06 1983-02-01 John Wyeth & Brother Limited Articles for carrying chemicals
US4749575A (en) * 1983-10-03 1988-06-07 Bio-Dar Ltd. Microencapsulated medicament in sweet matrix
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
US5433959A (en) * 1986-02-13 1995-07-18 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
US5464632A (en) * 1991-07-22 1995-11-07 Laboratoires Prographarm Rapidly disintegratable multiparticular tablet
US5501861A (en) * 1992-01-29 1996-03-26 Takeda Chemical Industries, Ltd. Fast dissolving tablet and its production
US5549911A (en) * 1994-01-14 1996-08-27 Laboratoires Des Produits Ethiques Ethypharm Galenic form of 5-nitromidazole derivatives which is effective for the treatment of parasitoses and infections of the entire gastrointestinal tract
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US5798120A (en) * 1993-10-12 1998-08-25 Tokyo Tanabe Company Limited Enteric granule-containing tablets
US5824339A (en) * 1995-09-08 1998-10-20 Takeda Chemical Industries, Ltd Effervescent composition and its production
US5855914A (en) * 1988-09-27 1999-01-05 Takeda Chemical Industries, Ltd. Granules having core and their production
US5900428A (en) * 1995-05-19 1999-05-04 Astra Aktiebolag Pharmacological use of AII-receptor antagonists
US5958453A (en) * 1996-10-31 1999-09-28 Takeda Chemical Industries, Ltd. Solid pharmaceutical preparation with improved buccal disintegrability and/or dissolubility
US6024981A (en) * 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
US6132770A (en) * 1996-01-08 2000-10-17 Astrazeneca Ab Multiple unit effervescent dosage forms comprising proton pump inhibitor
US20010003751A1 (en) * 1995-02-22 2001-06-14 Terashita Zen-Ichi Pharmaceutical composition for treating transient ischemic attack
US6287596B1 (en) * 1996-07-12 2001-09-11 Daiichi Pharmaceutical Co., Ltd. Quickly disintegratable compression-molded materials and process for producing the same
US6299904B1 (en) * 1997-05-27 2001-10-09 Takeda Chemical Industries, Ltd. Solid pharmaceutical preparation
US6328994B1 (en) * 1998-05-18 2001-12-11 Takeda Chemical Industries, Ltd. Orally disintegrable tablets
US6365184B1 (en) * 1996-01-08 2002-04-02 Astrazeneca Ab Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a NSAID
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6531152B1 (en) * 1998-09-30 2003-03-11 Dexcel Pharma Technologies Ltd. Immediate release gastrointestinal drug delivery system
US7070805B2 (en) * 1998-07-28 2006-07-04 Takeda Pharmaceutical Company Limited Rapidly disintegrable solid preparation

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5411226A (en) 1977-06-24 1979-01-27 Shin Etsu Chem Co Ltd Disintegratable granule
SE8404808L (en) 1983-10-03 1985-04-04 Avner Rotman MICROCAPCLE PLATE MEDICINE IN SOT MATRIX
US4612345A (en) * 1985-02-28 1986-09-16 The Dow Chemical Company Hydroxypropyl methyl cellulose ethers useful as suspending agents for suspension polymerization of vinyl chloride
GB8518301D0 (en) * 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
SE450087B (en) 1985-10-11 1987-06-09 Haessle Ab GRAINS WITH CONTROLLED RELEASE OF PHARMACIFICALLY ACTIVE SUBSTANCES APPLIED SIGNED ON A COMPACT INSULABLE NUCLEAR MATERIAL
CA1327010C (en) 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
US4786503A (en) * 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
US5030447A (en) 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
JPH0723304B2 (en) 1988-04-19 1995-03-15 三菱化学株式会社 Pharmaceutical component-immobilized composition
JPH0720858B2 (en) 1988-04-19 1995-03-08 三菱化学株式会社 Coated solid drug
US4910023A (en) 1988-06-09 1990-03-20 Warner-Lambert Company Drug in combination with flavor masking agent and method for making same
JPH0819003B2 (en) * 1988-09-27 1996-02-28 武田薬品工業株式会社 Nucleated granule and method for producing the same
GB8824392D0 (en) 1988-10-18 1988-11-23 Ciba Geigy Ag Dispersible formulation
IT1238072B (en) 1990-01-19 1993-07-03 Sclavo Spa PHARMACEUTICAL COMPOSITIONS AND DOSAGE FORMS FOR ORAL ADMINISTRATION OF CALCITONIN
DE69111287T2 (en) 1990-04-18 1995-12-21 Asahi Chemical Ind Spherical nuclei, spherical granules and processes for their production.
JPH0466538A (en) 1990-07-04 1992-03-02 Suntory Ltd Antiulcer agent
US5316772A (en) 1990-12-19 1994-05-31 Solvay & Cie, S.A. (Societe Anonyme) Bilayered oral pharmaceutical composition with pH dependent release
JP2820829B2 (en) 1991-03-07 1998-11-05 武田薬品工業株式会社 Nucleated powder and production method thereof
JP2682353B2 (en) * 1991-11-20 1997-11-26 武田薬品工業株式会社 Oral pharmaceutical composition and method for producing the same
US5200194A (en) * 1991-12-18 1993-04-06 Alza Corporation Oral osmotic device
JPH05310558A (en) 1992-05-07 1993-11-22 Lion Corp Solid preparation composition
JP3059004B2 (en) 1992-09-18 2000-07-04 ダイセル化学工業株式会社 Low-substituted hydroxypropylcellulose having high solubility in aqueous alkali solution and method for producing the same
JP2647338B2 (en) * 1993-02-10 1997-08-27 武田薬品工業株式会社 Uncoated tablet and method for producing the same
JPH06305962A (en) 1993-04-21 1994-11-01 Taisho Pharmaceut Co Ltd Therapeutic agent for atopic dermatitis
JP3502951B2 (en) 1993-07-06 2004-03-02 大正製薬株式会社 Hyperlipidemia treatment
IL110376A (en) 1993-08-02 1998-08-16 Bristol Myers Squibb Co Pharmaceutical compositions containing ifetroban salts and methods for the preparation thereof
DE69532110T2 (en) * 1994-01-31 2004-09-09 Yamanouchi Pharmaceutical Co., Ltd. INTRAORALLY SOLUBLE MOLDED PRESSURE AND METHOD FOR THE PRODUCTION THEREOF
US5380234A (en) * 1994-05-25 1995-01-10 Ledford; Kevin D. Inflatable and deflatable combatant action toy
SE9402431D0 (en) 1994-07-08 1994-07-08 Astra Ab New tablet formulation
JPH0827033A (en) 1994-07-14 1996-01-30 Nikken Chem Co Ltd Erythritol-containing solid agent
SE9500422D0 (en) 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
JPH08310969A (en) 1995-05-22 1996-11-26 Lion Corp Solid pharmaceutical composition and its preparation
US5658583A (en) 1995-07-28 1997-08-19 Zhang; Jie Apparatus and methods for improved noninvasive dermal administration of pharmaceuticals
JPH0948726A (en) 1995-08-07 1997-02-18 Tanabe Seiyaku Co Ltd Rapidly disintegrating preparation in mouth cavity and its production
JPH0971523A (en) 1995-09-07 1997-03-18 Riyuukakusan:Kk Tablet quickly disintegrating in oral cavity
SE9600072D0 (en) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
SE9600071D0 (en) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
US5840332A (en) 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
EA001089B1 (en) * 1996-02-29 2000-10-30 Фудзисава Фармасьютикал Ко., Лтд. Tablets containing beta -lactam antibiotic and process for producing the same
EP0799616A1 (en) 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Oral composition comprising a fumagillol derivative
DK0914818T3 (en) 1996-06-14 2005-07-04 Kyowa Hakko Kogyo Kk Intraoral fast disintegrable tablet
AU718350B2 (en) * 1996-11-15 2000-04-13 Ajinomoto Co., Inc. Tablet composition
JP3718341B2 (en) * 1998-05-12 2005-11-24 信越化学工業株式会社 Low substituted hydroxypropylcellulose and process for producing the same

Patent Citations (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4371516A (en) * 1976-10-06 1983-02-01 John Wyeth & Brother Limited Articles for carrying chemicals
US4749575A (en) * 1983-10-03 1988-06-07 Bio-Dar Ltd. Microencapsulated medicament in sweet matrix
US5433959A (en) * 1986-02-13 1995-07-18 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
US6380234B1 (en) * 1986-02-13 2002-04-30 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition and its production
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
US5855914A (en) * 1988-09-27 1999-01-05 Takeda Chemical Industries, Ltd. Granules having core and their production
US5464632A (en) * 1991-07-22 1995-11-07 Laboratoires Prographarm Rapidly disintegratable multiparticular tablet
US5464632C1 (en) * 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
US5501861A (en) * 1992-01-29 1996-03-26 Takeda Chemical Industries, Ltd. Fast dissolving tablet and its production
US5798120A (en) * 1993-10-12 1998-08-25 Tokyo Tanabe Company Limited Enteric granule-containing tablets
US5549911A (en) * 1994-01-14 1996-08-27 Laboratoires Des Produits Ethiques Ethypharm Galenic form of 5-nitromidazole derivatives which is effective for the treatment of parasitoses and infections of the entire gastrointestinal tract
US20010003751A1 (en) * 1995-02-22 2001-06-14 Terashita Zen-Ichi Pharmaceutical composition for treating transient ischemic attack
US5900428A (en) * 1995-05-19 1999-05-04 Astra Aktiebolag Pharmacological use of AII-receptor antagonists
US5824339A (en) * 1995-09-08 1998-10-20 Takeda Chemical Industries, Ltd Effervescent composition and its production
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6132770A (en) * 1996-01-08 2000-10-17 Astrazeneca Ab Multiple unit effervescent dosage forms comprising proton pump inhibitor
US6365184B1 (en) * 1996-01-08 2002-04-02 Astrazeneca Ab Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a NSAID
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6287596B1 (en) * 1996-07-12 2001-09-11 Daiichi Pharmaceutical Co., Ltd. Quickly disintegratable compression-molded materials and process for producing the same
US6248357B1 (en) * 1996-10-31 2001-06-19 Takeda Chemical Industries, Ltd. Solid pharmaceutical preparation with improved buccal disintegrability and/or dissolubility
US5958453A (en) * 1996-10-31 1999-09-28 Takeda Chemical Industries, Ltd. Solid pharmaceutical preparation with improved buccal disintegrability and/or dissolubility
US6024981A (en) * 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
US6299904B1 (en) * 1997-05-27 2001-10-09 Takeda Chemical Industries, Ltd. Solid pharmaceutical preparation
US6586004B2 (en) * 1997-05-27 2003-07-01 Takeda Chemical Industries, Ltd. Solid preparation
US6328994B1 (en) * 1998-05-18 2001-12-11 Takeda Chemical Industries, Ltd. Orally disintegrable tablets
US7070805B2 (en) * 1998-07-28 2006-07-04 Takeda Pharmaceutical Company Limited Rapidly disintegrable solid preparation
US6531152B1 (en) * 1998-09-30 2003-03-11 Dexcel Pharma Technologies Ltd. Immediate release gastrointestinal drug delivery system

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080152779A1 (en) * 2005-04-15 2008-06-26 Evelyne De Groote Instant Product
US20100034891A1 (en) * 2006-04-27 2010-02-11 Takeda Pharmaceutical Company Limited Taste-masking solid preparation of pioglitazone
US8632808B2 (en) 2006-04-27 2014-01-21 Takeda Pharmaceutical Company Limited Taste-masking solid preparation of pioglitazone
ES2328438A1 (en) * 2007-11-23 2009-11-12 Chiesi Farmaceutici S.P.A. Procedure to determine the polymorphic purity of minidipin dichlorhydrate (Machine-translation by Google Translate, not legally binding)
US20090155360A1 (en) * 2007-12-10 2009-06-18 Venkatesh Gopi M Orally disintegrating tablets comprising diphenhydramine
WO2009076361A1 (en) * 2007-12-10 2009-06-18 Eurand, Inc. Orally disintegrating tablets comprising diphenhydramine
US20090202516A1 (en) * 2008-02-08 2009-08-13 Prothera, Inc. Inhibition and treatment of gastrointestinal biofilms
US11078516B2 (en) 2008-02-08 2021-08-03 Prothera, Inc. Inhibition and treatment of gastrointestinal biofilms
US20110230656A1 (en) * 2010-03-18 2011-09-22 Shin-Etsu Chemical Co., Ltd. Low-Substituted Hydroxypropylcellulose and Solid Preparation Comprising the Same
US8822675B2 (en) 2010-03-18 2014-09-02 Shin-Etsu Chemical Co., Ltd. Low-substituted hydroxypropylcellulose and solid preparation comprising the same
US9850512B2 (en) 2013-03-15 2017-12-26 The Research Foundation For The State University Of New York Hydrolysis of cellulosic fines in primary clarified sludge of paper mills and the addition of a surfactant to increase the yield
US9951363B2 (en) 2014-03-14 2018-04-24 The Research Foundation for the State University of New York College of Environmental Science and Forestry Enzymatic hydrolysis of old corrugated cardboard (OCC) fines from recycled linerboard mill waste rejects

Also Published As

Publication number Publication date
DK1561458T3 (en) 2010-10-25
KR20010071026A (en) 2001-07-28
CY1110988T1 (en) 2015-06-11
ZA200100285B (en) 2002-01-10
JP2000344660A (en) 2000-12-12
HK1035501A1 (en) 2001-11-30
TW585786B (en) 2004-05-01
ATE291418T1 (en) 2005-04-15
ES2347968T3 (en) 2010-11-26
EP1561458A1 (en) 2005-08-10
WO2000006126A1 (en) 2000-02-10
JP2010132709A (en) 2010-06-17
US7399485B1 (en) 2008-07-15
JP4573397B2 (en) 2010-11-04
US20070254031A1 (en) 2007-11-01
CA2338792C (en) 2006-01-17
DK1100469T3 (en) 2005-04-18
ATE481090T1 (en) 2010-10-15
MY154010A (en) 2015-04-30
DE69924381D1 (en) 2005-04-28
US7070805B2 (en) 2006-07-04
HK1077742A1 (en) 2006-02-24
EP1100469A1 (en) 2001-05-23
SI1100469T1 (en) 2005-08-31
EP1561458B1 (en) 2010-09-15
CA2581111A1 (en) 2000-02-10
MY151098A (en) 2014-04-15
PT1561458E (en) 2010-10-11
US20010010825A1 (en) 2001-08-02
CN1149077C (en) 2004-05-12
PT1100469E (en) 2005-06-30
KR100536783B1 (en) 2005-12-14
JP2000103731A (en) 2000-04-11
TW200302742A (en) 2003-08-16
AR019935A1 (en) 2002-03-27
AU4802099A (en) 2000-02-21
AR080436A2 (en) 2012-04-11
TWI257311B (en) 2006-07-01
CN1310613A (en) 2001-08-29
JP3404648B2 (en) 2003-05-12
EP1100469B1 (en) 2005-03-23
CA2525555A1 (en) 2000-02-10
DE69942777D1 (en) 2010-10-28
CA2338792A1 (en) 2000-02-10
DE69924381T2 (en) 2006-04-20
ES2237121T3 (en) 2005-07-16

Similar Documents

Publication Publication Date Title
US7399485B1 (en) Rapidly Disintegrable solid preparation
CA2286753C (en) Solid pharmaceutical preparation
US8486450B2 (en) Method of producing solid preparation disintegrating in the oral cavity
DK2263660T3 (en) Orally disintegrating tablets.
JP4939680B2 (en) Solid preparation
CA2528646A1 (en) Solid pharmaceutical preparation

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION